BULL Pengajuan SEC - Webull Corporation- Laporan Tahunan, Pernyataan Kuasa, Prospektus

Mga Batayang Estadistika

CIK

1759186

SEC Filings

All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis. These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to Webull Corporation

SEC Filings (Chronological Order)

Halaman ini menyediakan daftar lengkap dan kronologis dari Pengajuan SEC, tidak termasuk pengajuan kepemilikan yang kami sediakan di tempat lain.

August 15, 2025	424B3	2,150,000 shares of Common Stock Pre-Funded Warrants to Purchase up to 1,350,000 Shares of Common Stock Series A Warrants to Purchase up to 3,062,500 shares of Common Stock and Series B Warrants to Purchase up to 3,062,500 shares of Common Stock (Sha COEPTIS THERAPEUTICS HOLDINGS, INC. Form 10-Q PROSPECTUS SUPPLEMENT NO. 10 Filed Pursuant to Rule 424(b)(3) (to prospectus dated June 14, 2023) Registration Statement No. 333-269782 2,150,000 shares of Common Stock Pre-Funded Warrants to Purchase up to 1,350,000 Shares of Common Stock Series A Warrants to Purchase up to 3,062,500 shares of Common Stock and Series B Warrants to Purchase up to 3,062
August 15, 2025	424B3	Up to 12,080,000 shares of Common Stock COEPTIS THERAPEUTICS HOLDINGS, INC. Form 10-Q PROSPECTUS SUPPLEMENT NO. 8 Filed Pursuant to Rule 424(b)(3) (to prospectus dated November 29, 2023) Registration Statement No. 333-275558 Up to 12,080,000 shares of Common Stock This prospectus supplement (the “Prospectus Supplement”) updates and supplements the prospectus dated November 29, 2023 (the “Prospectus”), which forms a part of our Registrat
August 15, 2025	424B3	Up to 3,919,349 shares of Common Stock by Selling Stockholders COEPTIS THERAPEUTICS HOLDINGS, INC. Form 10-Q PROSPECTUS SUPPLEMENT NO. 3 Filed Pursuant to Rule 424(b)(3) (to prospectus dated April 21, 2025) Registration Statement No. 333-284230 Up to 3,919,349 shares of Common Stock by Selling Stockholders This prospectus supplement (the “Prospectus Supplement”) updates and supplements the prospectus dated April 21, 2025 (the “Prospectus”), which forms a part
August 14, 2025	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ Quarterly REPORT PURSUANT to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended June 30, 2025 or ☐ TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transaction period from to Commission File No. 001-39669 COEPTIS THER
August 11, 2025	S-4/A	As filed with the Securities and Exchange Commission on August 8, 2025 Table of Contents As filed with the Securities and Exchange Commission on August 8, 2025 Registration No.
August 11, 2025	EX-10.24	Master Custody Services Agreement between Anchorage Digital Bank N.A. and Z Squared Inc. Exhibit 10.24 CERTAIN INFORMATION INDICATED BY [***] HAS BEEN OMITTED AS NOT MATERIAL AND PRIVATE OR CONFIDENTIAL MASTER SERVICES AGREEMENT This Master Services Agreement (this “Agreement”), executed on July 26, 2025, be effective as of the date the Securities Exchange Commission (“SEC”) declares effective the Form S-4 filed with the SEC by Coeptis Therapeutics Holdings, Inc. on June 26, 2025, as
August 11, 2025	EX-10.23	Amended and Restated Asset-For-Share Exchange Agreement between BSG Series CM, LLC and Z Squared Inc., dated June 24, 2025. Exhibit 10.23 AMENDED AND RESTATED ASSET-FOR-SHARE EXCHANGE AGREEMENT THIS AMENDED AND RESTATED ASSET-FOR-SHARE EXCHANGE AGREEMENT (the “Agreement”) is made and entered into as of June 24, 2025, by and between Z Squared Inc., a Wyoming corporation (“Z Squared”) and BSG Series CM a South Carolina Limited Liability Company (“Transferor”). RECITALS WHEREAS, Transferor owns certain computer equipment
June 26, 2025	EX-99.6	Consent of Bryan Fuerst to be named a Director Exhibit 99.6 Consent to be Named as a Director Nominee In connection with the filing by Coeptis Therapeutics Holdings, Inc. of the Registration Statement on Form S-4 with the Securities and Exchange Commission under the Securities Act of 1933, as amended (the “Securities Act”), I hereby consent, pursuant to Rule 438 of the Securities Act, to being named as a nominee to the board of directors of Co
June 26, 2025	EX-99.5	Consent of Kenneth Cooper to be named a Director Exhibit 99.5 Consent to be Named as a Director Nominee In connection with the filing by Coeptis Therapeutics Holdings, Inc. of the Registration Statement on Form S-4 with the Securities and Exchange Commission under the Securities Act of 1933, as amended (the “Securities Act”), I hereby consent, pursuant to Rule 438 of the Securities Act, to being named as a nominee to the board of directors of Co
June 26, 2025	EX-2.2	Limited Waiver and First Amendment to Merger Agreement, dated as of May 27, 2025 Exhibit 2.2 LIMITED WAIVER AND FIRST AMENDMENT TO MERGER AGREEMENT This Limited Waiver and First Amendment to Merger Agreement (this “Amendment”) is made effective as of May 27, 2025 (the “Effective Date”), by and between Z Squared Inc., a Wyoming corporation (the “Company”) and Coeptis Therapeutics Holdings Inc., a Delaware corporation (“Purchaser”). The Company and Purchaser are referred to here
June 26, 2025	EX-FILING FEES	Filing Fee Table Exhibit 107 Calculation of Filing Fee Tables FORM S-1 (Form Type) COEPTIS THERAPEUTICS HOLDINGS, INC.
June 26, 2025	EX-99.7	Consent of David Halabu to be named a Director Exhibit 99.7 Consent to be Named as a Director Nominee In connection with the filing by Coeptis Therapeutics Holdings, Inc. of the Registration Statement on Form S-4 with the Securities and Exchange Commission under the Securities Act of 1933, as amended (the “Securities Act”), I hereby consent, pursuant to Rule 438 of the Securities Act, to being named as a nominee to the board of directors of Co
June 26, 2025	EX-2.4	Limited Waiver and Third Amendment to Merger Agreement, dated as of June 20, 2025 Exhibit 2.4 LIMITED WAIVER AND THIRD AMENDMENT TO MERGER AGREEMENT This Limited Waiver and Third Amendment to Merger Agreement (this “Amendment”) is made effective as of June 20, 2025 (the “Effective Date”), by and between Z Squared Inc., a Wyoming corporation (the “Company”) and Coeptis Therapeutics Holdings Inc., a Delaware corporation (“Purchaser”). The Company and Purchaser are referred to her
June 26, 2025	S-4	As filed with the Securities and Exchange Commission on June 25, 2025 Table of Contents As filed with the Securities and Exchange Commission on June 25, 2025 Registration No.
June 26, 2025	EX-21.1	Subsidiaries of Coeptis Therapeutics Holdings, Inc. Exhibit 21.1 Subsidiaries of Coeptis Therapeutics Holdings, Inc. Coeptis Therapeutics, Inc. Delaware Coeptis Pharmaceuticals, Inc. Delaware Coeptis Pharmaceuticals LLC Pennsylvania GEAR Therapeutics Inc. Florida SNAP Biosciences Inc. Florida
June 26, 2025	EX-99.2	Coeptis Therapeutics Holdings, Inc. & Z Squared Inc Fairness Opinion Prepared by: Sun Business Valuations, LLC Report Date: May 12, 2025 Effective Date: May 12, 2025 Exhibit 99.2 Coeptis Therapeutics Holdings, Inc. & Z Squared Inc Fairness Opinion Prepared by: Sun Business Valuations, LLC Report Date: May 12, 2025 Effective Date: May 12, 2025 1 Coeptis Therapeutics Holdings, Inc. 2 Confidential Valuation Analysis for Coeptis Therapeutics Holdings, Inc . Prepared by: Sun Business Valuations, LLC May 12, 2025 CONFIDENTIAL Coeptis Therapeutics Holdings, Inc. 3 Co
June 26, 2025	EX-99.4	Consent of Michelle Burke to be named a Director Exhibit 99.4 Consent to be Named as a Director Nominee In connection with the filing by Coeptis Therapeutics Holdings, Inc. of the Registration Statement on Form S-4 with the Securities and Exchange Commission under the Securities Act of 1933, as amended (the “Securities Act”), I hereby consent, pursuant to Rule 438 of the Securities Act, to being named as a nominee to the board of directors of Co
June 26, 2025	EX-99.3	Consent of Sun Business Valuations, LLC Exhibit 99.3 Consent of Sun Business Valuations, LLC We hereby consent to (i) the inclusion of our opinion letter, dated May 12, 2025, to the Board of Directors of Coeptis Therapeutics Holdings, Inc. as an Annex to the Proxy Statement/Prospectus which forms a part of the Registration Statement on Form S-4 related to the proposed merger with Z Squared Inc. and (ii) the references to such opinion th
June 26, 2025	EX-2.3	Limited Waiver and Second Amendment to Merger Agreement, dated as of June 10, 2025 Exhibit 2.3 LIMITED WAIVER AND SECOND AMENDMENT TO MERGER AGREEMENT This Limited Waiver and Second Amendment to Merger Agreement (this “Amendment”) is made effective as of June 10, 2025 (the “Effective Date”), by and between Z Squared Inc., a Wyoming corporation (the “Company”) and Coeptis Therapeutics Holdings Inc., a Delaware corporation (“Purchaser”). The Company and Purchaser are referred to h
June 26, 2025	EX-99.8	Consent of Adam Sohn to be named a Director Exhibit 99.8 Consent to be Named as a Director Nominee In connection with the filing by Coeptis Therapeutics Holdings, Inc. of the Registration Statement on Form S-4 with the Securities and Exchange Commission under the Securities Act of 1933, as amended (the “Securities Act”), I hereby consent, pursuant to Rule 438 of the Securities Act, to being named as a nominee to the board of directors of Co
June 3, 2025	EX-97	Coeptis Therapeutics Holdings, Inc. Clawback Policy Exhibit 97 COEPTIS THERAPEUTICS HOLDINGS, INC. RULE 10D-1 CLAWBACK POLICY The purpose of this Nasdaq Executive Compensation Recovery Policy of the Company (as amended from time to time, the “Policy”) is to describe the circumstances in which current and former Executive Officers will be required to repay or return Erroneously Awarded Compensation to members of the Company and its affiliates. The C
June 3, 2025	10-K/A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K/A (Amendment No. 1) UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K/A (Amendment No. 1) (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Fiscal Year Ended December 31, 2024 Or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-
May 15, 2025	424B3	Up to 3,919,349 shares of Common Stock by Selling Stockholders PROSPECTUS SUPPLEMENT NO. 2 Filed Pursuant to Rule 424(b)(3) (to prospectus dated April 21, 2025) Registration Statement No. 333-284230 Up to 3,919,349 shares of Common Stock by Selling Stockholders This prospectus supplement (the “Prospectus Supplement”) updates and supplements the prospectus dated April 21, 2025 (the “Prospectus”), which forms a part of our Registration Statement on Form S-1 (Re
May 15, 2025	424B3	Up to 12,080,000 shares of Common Stock PROSPECTUS SUPPLEMENT NO. 7 Filed Pursuant to Rule 424(b)(3) (to prospectus dated November 29, 2023) Registration Statement No. 333-275558 Up to 12,080,000 shares of Common Stock This prospectus supplement (the “Prospectus Supplement”) updates and supplements the prospectus dated November 29, 2023 (the “Prospectus”), which forms a part of our Registration Statement on Form S-1 (Registration No. 33
May 15, 2025	424B3	2,150,000 shares of Common Stock Pre-Funded Warrants to Purchase up to 1,350,000 Shares of Common Stock Series A Warrants to Purchase up to 3,062,500 shares of Common Stock and Series B Warrants to Purchase up to 3,062,500 shares of Common Stock (Sha PROSPECTUS SUPPLEMENT NO. 9 Filed Pursuant to Rule 424(b)(3) (to prospectus dated June 14, 2023) Registration Statement No. 333-269782 2,150,000 shares of Common Stock Pre-Funded Warrants to Purchase up to 1,350,000 Shares of Common Stock Series A Warrants to Purchase up to 3,062,500 shares of Common Stock and Series B Warrants to Purchase up to 3,062,500 shares of Common Stock (Shares of Common S
May 14, 2025	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ Quarterly REPORT PURSUANT to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended March 31, 2025 or ☐ TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transaction period from to Commission File No. 001-39669 COEPTIS THE
April 28, 2025	8-K	SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of Earliest Event Reported): April 25, 2025 COEPTIS THERAPEUTICS HOLDINGS, I SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of Earliest Event Reported): April 25, 2025 COEPTIS THERAPEUTICS HOLDINGS, INC. (Exact name of registrant as specified in its charter) Delaware 001-39669 98-1465952 (State or other jurisdiction of incorporation) (Commission Fi
April 28, 2025	EX-10.1	Form of Voting Agreement, dated as of April 25, 2025, by and among Z Squared and certain stockholders of Coeptis. Exhibit 10.1 Purchaser Voting Agreement This Voting Agreement (this “Agreement”), dated as of April , 2025, is entered into by and between the undersigned stockholders (each, “Stockholder” and, collectively, “Stockholders”) of Coeptis Therapeutics Holdings Inc., a Delaware corporation (“Purchaser”), and Z Squared Inc., a Wyoming corporation (the “Company”). Company and Stockholders are each someti
April 28, 2025	424B3	2,150,000 shares of Common Stock Pre-Funded Warrants to Purchase up to 1,350,000 Shares of Common Stock Series A Warrants to Purchase up to 3,062,500 shares of Common Stock and Series B Warrants to Purchase up to 3,062,500 shares of Common Stock (Sha PROSPECTUS SUPPLEMENT NO. 8 Filed Pursuant to Rule 424(b)(3) (to prospectus dated June 14, 2023) Registration Statement No. 333-269782 2,150,000 shares of Common Stock Pre-Funded Warrants to Purchase up to 1,350,000 Shares of Common Stock Series A Warrants to Purchase up to 3,062,500 shares of Common Stock and Series B Warrants to Purchase up to 3,062,500 shares of Common Stock (Shares of Common S
April 28, 2025	EX-99.1	Coeptis Therapeutics, Inc. and Z Squared Inc. Announce Merger Agreement Aim to create the largest publicly-traded, Dogecoin-focused mining company in the world Coeptis to spin out biopharmaceutical operations Exhibit 99.1 Coeptis Therapeutics, Inc. and Z Squared Inc. Announce Merger Agreement Aim to create the largest publicly-traded, Dogecoin-focused mining company in the world Coeptis to spin out biopharmaceutical operations Wexford, PA April 25, 2025 – Coeptis Therapeutics Holdings, Inc. (Nasdaq; COEP) (“Coeptis” or the “Company”), a biopharmaceutical and technology company focused on developing inn
April 28, 2025	EX-2.1	Agreement and Plan of Merger, dated as of April 25, 2025, by and among Coeptis, Merger Sub and Z Squared. Exhibit 2.1 AGREEMENT AND PLAN OF MERGER by and among COEPTIS THERAPEUTICS HOLDINGS INC., as the Purchaser, CP MERGER SUB INC., as Merger Sub, and Z SQUARED INC., as the Company, Dated as of April 25, 2025 [THIS DRAFT IS SUBJECT TO CHANGE BASED ON THE PROSPECTIVE PURCHASER’S DUE DILIGENCE INVESTIGATION. THERE ARE NO BINDING OFFERS OR AGREEMENTS UNLESS AND UNTIL A FULLY EXECUTED DEFINITIVE AGREEMEN
April 28, 2025	424B3	Up to 12,080,000 shares of Common Stock PROSPECTUS SUPPLEMENT NO. 6 Filed Pursuant to Rule 424(b)(3) (to prospectus dated November 29, 2023) Registration Statement No. 333-275558 Up to 12,080,000 shares of Common Stock This prospectus supplement (the “Prospectus Supplement”) updates and supplements the prospectus dated November 29, 2023 (the “Prospectus”), which forms a part of our Registration Statement on Form S-1 (Registration No. 33
April 28, 2025	424B3	Up to 3,919,349 shares of Common Stock by Selling Stockholders PROSPECTUS SUPPLEMENT NO. 1 Filed Pursuant to Rule 424(b)(3) (to prospectus dated April 21, 2025) Registration Statement No. 333-284230 Up to 3,919,349 shares of Common Stock by Selling Stockholders This prospectus supplement (the “Prospectus Supplement”) updates and supplements the prospectus dated April 21, 2025 (the “Prospectus”), which forms a part of our Registration Statement on Form S-1 (Re
April 23, 2025	424B4	Up to 3,919,349 shares of Common Stock by Selling Stockholders Filed Pursuant to Rule 424(b)(4) Registration Statement No. 333-284230 Up to 3,919,349 shares of Common Stock by Selling Stockholders This prospectus relates to the resale from time to time by the selling stockholders named in this prospectus (the “Selling Stockholders”) of up to 3,919,349 shares of our common stock, par value $0.0001 per share (“Common Stock”), which includes: (i) 100,000 shares
April 18, 2025	CORRESP	Coeptis Therapeutics Holdings, Inc. 105 Bradford Rd, Suite 420 Wexford, Pennsylvania 15090 Coeptis Therapeutics Holdings, Inc. 105 Bradford Rd, Suite 420 Wexford, Pennsylvania 15090 April 18, 2025 VIA EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences 100 F Street, N.E. Washington, DC 20549 Attention: Joshua Gursky Re: Coeptis Therapeutics Holdings, Inc. Registration Statement on Form S-1 Filed on January 10, 2025 File No. 333-284230 La
April 4, 2025	EX-FILING FEES	Filing Fee Table Exhibit 107 Calculation of Filing Fee Tables FORM S-1 (Form Type) COEPTIS THERAPEUTICS HOLDINGS, INC.
April 4, 2025	S-1/A	As filed with the Securities and Exchange Commission on April 3, 2025 Table of Contents As filed with the Securities and Exchange Commission on April 3, 2025 Registration No.
April 2, 2025	424B3	2,150,000 shares of Common Stock Pre-Funded Warrants to Purchase up to 1,350,000 Shares of Common Stock Series A Warrants to Purchase up to 3,062,500 shares of Common Stock and Series B Warrants to Purchase up to 3,062,500 shares of Common Stock (Sha PROSPECTUS SUPPLEMENT NO. 7 Filed Pursuant to Rule 424(b)(3) (to prospectus dated June 14, 2023) Registration Statement No. 333-269782 2,150,000 shares of Common Stock Pre-Funded Warrants to Purchase up to 1,350,000 Shares of Common Stock Series A Warrants to Purchase up to 3,062,500 shares of Common Stock and Series B Warrants to Purchase up to 3,062,500 shares of Common Stock (Shares of Common S
April 2, 2025	424B3	Up to 12,080,000 shares of Common Stock PROSPECTUS SUPPLEMENT NO. 5 Filed Pursuant to Rule 424(b)(3) (to prospectus dated November 29, 2023) Registration Statement No. 333-275558 Up to 12,080,000 shares of Common Stock This prospectus supplement (the “Prospectus Supplement”) updates and supplements the prospectus dated November 29, 2023 (the “Prospectus”), which forms a part of our Registration Statement on Form S-1 (Registration No. 33
March 28, 2025	EX-21.1	Subsidiaries of Coeptis Therapeutics Holdings, Inc. Exhibit 21.1 Subsidiaries of Coeptis Therapeutics Holdings, Inc. Coeptis Therapeutics, Inc. Delaware Coeptis Pharmaceuticals, Inc. Delaware Coeptis Pharmaceuticals LLC Pennsylvania GEAR Therapeutics, Inc. Florida SNAP Biosciences, Inc. Florida
March 28, 2025	EX-19.1	Insider Trading Policies and Procedures Exhibit 19.1 COEPTIS THERAPEUTICS HOLDINGS, INC. INSIDER TRADING COMPLIANCE POLICY This Insider Trading Compliance Policy (this “Policy”) consists of seven sections: • Section I provides an overview; • Section II sets forth the policies of the Company prohibiting insider trading; • Section III explains insider trading; • Section IV consists of procedures that have been put in place by the Company
March 28, 2025	10-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Fiscal Year Ended December 31, 2024 Or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39
March 27, 2025	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of Earliest Event Reported): March 21, 2025 COEPTIS THERAPEUTICS HOLDINGS, INC. (Exact name of registrant as specified in its charter) Delaware 001-39669 98-1465952 (State or other jurisdiction of incorporation) (Commission Fi
February 7, 2025	EX-FILING FEES	Filing Fee Table Exhibit 107 Calculation of Filing Fee Tables FORM S-1 (Form Type) COEPTIS THERAPEUTICS HOLDINGS, INC.
February 7, 2025	S-1/A	As filed with the Securities and Exchange Commission on February 7, 2025 Table of Contents As filed with the Securities and Exchange Commission on February 7, 2025 Registration No.
January 24, 2025	8-K	Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Financial Statements and Exhibits SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of Earliest Event Reported): January 17, 2025 COEPTIS THERAPEUTICS HOLDINGS, INC. (Exact name of registrant as specified in its charter) Delaware 001-39669 98-1465952 (State or other jurisdiction of incorporation) (Commission
January 24, 2025	EX-10.1	Convertible Promissory Note issued to TA II PN, Ltd. Exhibit 10.1 NEITHER THIS NOTE NOR THE SECURITIES INTO WHICH THIS NOTE IS CONVERTIBLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE. THESE SECURITIES HAVE BEEN SOLD IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSU
January 22, 2025	8-K	Financial Statements and Exhibits, Other Events SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of Earliest Event Reported): January 21, 2025 COEPTIS THERAPEUTICS HOLDINGS, INC. (Exact name of registrant as specified in its charter) Delaware 001-39669 98-1465952 (State or other jurisdiction of incorporation) (Commission
January 22, 2025	EX-99.1	Coeptis Therapeutics Regains Compliance with Nasdaq Listing Rule 5550(a)(2) Exhibit 99.1 Coeptis Therapeutics Regains Compliance with Nasdaq Listing Rule 5550(a)(2) WEXFORD, PA., January 22, 2025 /PRNewswire/ - Coeptis Therapeutics Holdings, Inc. (Nasdaq: COEP) (the "Company" or "Coeptis"), a biopharmaceutical company focused on pioneering cell therapy platforms for cancer, autoimmune, and infectious diseases, today announced it has regained compliance with Listing Rule 5
January 10, 2025	S-1	As filed with the Securities and Exchange Commission on January 10, 2025 Table of Contents As filed with the Securities and Exchange Commission on January 10, 2025 Registration No.
January 10, 2025	EX-FILING FEES	Filing Fee Table Exhibit 107 Calculation of Filing Fee Tables FORM S-1 (Form Type) COEPTIS THERAPEUTICS HOLDINGS, INC.
January 10, 2025	EX-21.1	Subsidiaries of Coeptis Therapeutics Holdings, Inc. Exhibit 21.1 Subsidiaries of Coeptis Therapeutics Holdings, Inc. Coeptis Therapeutics, Inc. Delaware Coeptis Pharmaceuticals, Inc. Delaware Coeptis Pharmaceuticals LLC Pennsylvania GEAR Therapeutics Inc. Florida SNAP Biosciences Inc. Florida
December 27, 2024	8-K	Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits, Other Events SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of Earliest Event Reported): December 26, 2024 COEPTIS THERAPEUTICS HOLDINGS, INC. (Exact name of registrant as specified in its charter) Delaware 001-39669 98-1465952 (State or other jurisdiction of incorporation) (Commission
December 27, 2024	EX-99.1	CERTIFICATE OF AMENDMENT AMENDED AND RESTATED CERTIFICATE OF INCORPORATION COEPTIS THERAPEUTICS HOLDINGS, INC. Exhibit 99.1 CERTIFICATE OF AMENDMENT OF AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF COEPTIS THERAPEUTICS HOLDINGS, INC. Coeptis Therapeutics Holdings, Inc. (the “Corporation”), a corporation organized and existing by virtue of the General Corporation Law of the State of Delaware (the “DGCL”), hereby certifies as follows: 1. That the Corporation was originally formed under the name Bull H
December 27, 2024	EX-99.2	Coeptis Therapeutics Announces Reverse Stock Split Exhibit 99.2 Coeptis Therapeutics Announces Reverse Stock Split WEXFORD, PA., Dec. 27, 2024 /PRNewswire/ - Coeptis Therapeutics Holdings, Inc. (Nasdaq: COEP) (the "Company" or "Coeptis"), a biopharmaceutical company focused on pioneering cell therapy platforms for cancer, autoimmune, and infectious diseases, today announced it will proceed with a 1-for-40 reverse stock split (the “Reverse Split”)
December 20, 2024	8-K	Submission of Matters to a Vote of Security Holders SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of Earliest Event Reported): December 18, 2024 COEPTIS THERAPEUTICS HOLDINGS, INC. (Exact name of registrant as specified in its charter) Delaware 001-39669 98-1465952 (State or other jurisdiction of incorporation) (Commission
December 17, 2024	EX-99.1	Coeptis Therapeutics Unveils New Technology Division: Coeptis Technologies Exhibit 99.1 Coeptis Therapeutics Unveils New Technology Division: Coeptis Technologies Coeptis Technologies Signs Binding Letter of Intent to Acquire Key Assets from a Risk Mitigation Software Company with 10,000 customers in over 100 countries, Expanding into the Booming Data Security Sector following the upcoming acquisition of NexGenAI Affiliates Network WEXFORD, PA., December 12, 2024 Coeptis
December 17, 2024	8-K	Financial Statements and Exhibits, Other Events SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of Earliest Event Reported): December 12, 2024 COEPTIS THERAPEUTICS HOLDINGS, INC. (Exact name of registrant as specified in its charter) Delaware 001-39669 98-1465952 (State or other jurisdiction of incorporation) (Commission
December 4, 2024	8-K	Financial Statements and Exhibits, Other Events SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of Earliest Event Reported): December 3, 2024 COEPTIS THERAPEUTICS HOLDINGS, INC. (Exact name of registrant as specified in its charter) Delaware 001-39669 98-1465952 (State or other jurisdiction of incorporation) (Commission
December 4, 2024	EX-99.1	Coeptis Therapeutics Executes Binding Letter of Intent to Acquire AI-Powered Marketing Solutions for Biotech, Pharmaceutical and Other Industries The Acquisition of NexGenAI Affiliates Network Expands Company’s Capabilities and Drives Innovation, Ope Exhibit 99.1 Coeptis Therapeutics Executes Binding Letter of Intent to Acquire AI-Powered Marketing Solutions for Biotech, Pharmaceutical and Other Industries The Acquisition of NexGenAI Affiliates Network Expands Company’s Capabilities and Drives Innovation, Operational Efficiency, and Opportunity for Growth WEXFORD, PA., December 3, 2024 - - Coeptis Therapeutics Holdings, Inc. (Nasdaq: COEP) (th
November 22, 2024	424B3	Up to 12,080,000 shares of Common Stock PROSPECTUS SUPPLEMENT NO. 4 Filed Pursuant to Rule 424(b)(3) (to prospectus dated November 29, 2023) Registration Statement No. 333-275558 Up to 12,080,000 shares of Common Stock This prospectus supplement (the “Prospectus Supplement”) updates and supplements the prospectus dated November 29, 2023 (the “Prospectus”), which forms a part of our Registration Statement on Form S-1 (Registration No. 33
November 22, 2024	424B3	2,150,000 shares of Common Stock Pre-Funded Warrants to Purchase up to 1,350,000 Shares of Common Stock Series A Warrants to Purchase up to 3,062,500 shares of Common Stock and Series B Warrants to Purchase up to 3,062,500 shares of Common Stock (Sha PROSPECTUS SUPPLEMENT NO. 6 Filed Pursuant to Rule 424(b)(3) (to prospectus dated June 14, 2023) Registration Statement No. 333-269782 2,150,000 shares of Common Stock Pre-Funded Warrants to Purchase up to 1,350,000 Shares of Common Stock Series A Warrants to Purchase up to 3,062,500 shares of Common Stock and Series B Warrants to Purchase up to 3,062,500 shares of Common Stock (Shares of Common S
November 14, 2024	SC 13G/A	COEP / Coeptis Therapeutics Holdings, Inc. / ARMISTICE CAPITAL, LLC Passive Investment SC 13G/A 1 armistice-coep093024a1.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 1)* Coeptis Therapeutics Holdings, Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 19207A108 (CUSIP Number) September 30, 2024 (Date of Event Which Requires Filing of this S
November 14, 2024	DEF 14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Defi
November 13, 2024	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 or ¨ TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transaction period from to Commission File No. 001-39669 COEPTIS
November 6, 2024	8-K	Entry into a Material Definitive Agreement, Financial Statements and Exhibits SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of Earliest Event Reported): November 1, 2024 COEPTIS THERAPEUTICS HOLDINGS, INC. (Exact name of registrant as specified in its charter) Delaware 001-39669 98-1465952 (State or other jurisdiction of incorporation) (Commission
November 6, 2024	EX-10.2	Form of Convertible Promissory Note issued to YA II PN, Ltd. Exhibit 10.2 NEITHER THIS NOTE NOR THE SECURITIES INTO WHICH THIS NOTE IS CONVERTIBLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE. THESE SECURITIES HAVE BEEN SOLD IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSU
November 6, 2024	EX-10.1	Standby Equity Purchase Agreement, dated November 1, 2024, between Coeptis Therapeutics Holdings, Inc. and YA II PN, Ltd. Exhibit 10.1 STANDBY EQUITY PURCHASE AGREEMENT THIS STANDBY EQUITY PURCHASE AGREEMENT (this “Agreement”) dated as of November 1, 2024 is made by and between YA II PN, LTD., a Cayman Islands exempt limited partnership (the “Investor”), and COEPTIS THERAPEUTICS HOLDINGS, INC., a Delaware corporation (the “Company”). The Investor and the Company may be referred to herein individually as a “Party” and
November 6, 2024	EX-10.3	Registration Rights Agreement, dated November 1, 2024, between Coeptis Therapeutics Holdings, Inc. and YA II PN, Ltd. Exhibit 10.3 REGISTRATION RIGHTS AGREEMENT THIS REGISTRATION RIGHTS AGREEMENT (this “Agreement”) dated as of November 1, 2024 is made by and between YA II PN, LTD., a Cayman Islands exempt limited partnership (the “Investor”), and COEPTIS THERAPEUTICS HOLDINGS, INC., a company incorporated under the laws of the State of Delaware (the “Company”). The Investor and the Company may be referred to here
November 4, 2024	PRE 14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☒ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Defi
September 30, 2024	EX-16.1	Letter of Turner, Stone & Company, LLP dated September 30, 2024 Exhibit 16.1 September 30, 2024 Securities and Exchange Commission 100 F Street, N. E. Washington, D.C. 20549-7561 Dear Sirs/Madams: We have read Item 4.01 of Coeptis Therapeutics Holdings, Inc.’s Form 8-K dated September 30, 2024, and have the following comments: 1. We agree with the statements made in the second through fifth paragraphs. 2. We have no basis on which to agree or disagree with the
September 30, 2024	8-K	Financial Statements and Exhibits, Changes in Registrant's Certifying Accountant SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of Earliest Event Reported): September 30, 2024 COEPTIS THERAPEUTICS HOLDINGS, INC. (Exact name of registrant as specified in its charter) Delaware 001-39669 98-1465952 (State or other jurisdiction of incorporation) (Commissio
September 19, 2024	8-K	Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Financial Statements and Exhibits, Other Events SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of Earliest Event Reported): September 17, 2024 COEPTIS THERAPEUTICS HOLDINGS, INC. (Exact name of registrant as specified in its charter) Delaware 001-39669 98-1465952 (State or other jurisdiction of incorporation) (Commissio
September 19, 2024	EX-99.1	Coeptis Therapeutics Granted Continued Listing from Nasdaq Hearings Panel to Regain Compliance with Nasdaq Listing Requirements Exhibit 99.1 Coeptis Therapeutics Granted Continued Listing from Nasdaq Hearings Panel to Regain Compliance with Nasdaq Listing Requirements WEXFORD, PA., September 19, 2024 - - Coeptis Therapeutics Holdings, Inc. (Nasdaq: COEP) (the "Company" or "Coeptis"), a biopharmaceutical company developing innovative cell therapy platforms for cancer, autoimmune, and infectious diseases, announced today tha
August 16, 2024	424B3	2,150,000 shares of Common Stock Pre-Funded Warrants to Purchase up to 1,350,000 Shares of Common Stock Series A Warrants to Purchase up to 3,062,500 shares of Common Stock and Series B Warrants to Purchase up to 3,062,500 shares of Common Stock (Sha PROSPECTUS SUPPLEMENT NO. 5 Filed Pursuant to Rule 424(b)(3) (to prospectus dated June 14, 2023) Registration Statement No. 333-269782 2,150,000 shares of Common Stock Pre-Funded Warrants to Purchase up to 1,350,000 Shares of Common Stock Series A Warrants to Purchase up to 3,062,500 shares of Common Stock and Series B Warrants to Purchase up to 3,062,500 shares of Common Stock (Shares of Common S
August 16, 2024	EX-21.1	Subsidiaries of Coeptis Therapeutics Holdings, Inc. Exhibit 21.1 Subsidiaries of Coeptis Therapeutics Holdings, Inc. Coeptis Therapeutics, Inc. Delaware Coeptis Pharmaceuticals, Inc. Delaware Coeptis Pharmaceuticals LLC Pennsylvania
August 16, 2024	424B3	Up to 12,080,000 shares of Common Stock PROSPECTUS SUPPLEMENT NO. 3 Filed Pursuant to Rule 424(b)(3) (to prospectus dated November 29, 2023) Registration Statement No. 333-275558 Up to 12,080,000 shares of Common Stock This prospectus supplement (the “Prospectus Supplement”) updates and supplements the prospectus dated November 29, 2023 (the “Prospectus”), which forms a part of our Registration Statement on Form S-1 (Registration No. 33
August 16, 2024	10-Q/A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q/A (Amendment No. 2) Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q/A (Amendment No. 2) x Quarterly REPORT PURSUANT to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended September 30, 2023 or ¨ TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transaction period from to Commission File N
August 16, 2024	10-K/A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K/A (Amendment No. 1) Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K/A (Amendment No. 1) (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Fiscal Year Ended December 31, 2023 Or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission
August 16, 2024	10-Q/A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q/A (Amendment No. 1) Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q/A (Amendment No. 1) ☒ Quarterly REPORT PURSUANT to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended March 31, 2024 or ☐ TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transaction period from to Commission File No. 0
August 16, 2024	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ Quarterly REPORT PURSUANT to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended June 30, 2024 or ☐ TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transaction period from to Commission File No. 001-39669 COEPTIS THER
August 14, 2024	8-K	Non-Reliance on Previously Issued Financial Statements or a Related Audit Report or Completed Interim Review SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of Earliest Event Reported): August 9, 2024 COEPTIS THERAPEUTICS HOLDINGS, INC. (Exact name of registrant as specified in its charter) Delaware 001-39669 98-1465952 (State or other jurisdiction of incorporation) (Commission Fi
August 14, 2024	NT 10-Q	UNITED STATES UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 12b-25 NOTIFICATION OF LATE FILING (Check one): o Form 10-K o Form 20-F o Form 11-K x Form 10-Q o Form 10-D o Form N-SAR o Form N-CSR For Period Ended: June 30, 2024 o Transition Report on Form 10-K o Transition Report on Form 20-F o Transition Report on Form 11-K o Transition Report on Form 10-Q o Transition Report on Form N-SAR For the Transition Period Ended: Read Instruction (on back page) Before Preparing Form.
July 31, 2024	8-K	Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of Earliest Event Reported): July 30, 2024 COEPTIS THERAPEUTICS HOLDINGS, INC. (Exact name of registrant as specified in its charter) Delaware 001-39669 98-1465952 (State or other jurisdiction of incorporation) (Commission Fil
June 20, 2024	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Unregistered Sales of Equity Securities, Financial Statements and Exhibits, Other Events SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of Earliest Event Reported): June 14, 2024 COEPTIS THERAPEUTICS HOLDINGS, INC. (Exact name of registrant as specified in its charter) Delaware 001-39669 98-1465952 (State or other jurisdiction of incorporation) (Commission Fil
June 20, 2024	EX-99.2	Coeptis Therapeutics Closes on $4.3 Million of Series A Preferred Offering Bolsters Company’s Corporate Mission Financing Led by Board Member and Priced at Premium to Market Price Exhibit 99.2 Coeptis Therapeutics Closes on $4.3 Million of Series A Preferred Offering Bolsters Company’s Corporate Mission Financing Led by Board Member and Priced at Premium to Market Price WEXFORD, PA., June 20, 2024 - Coeptis Therapeutics Holdings, Inc. (Nasdaq: COEP) (the “Company” or “Coeptis”), a biopharmaceutical company developing innovative cell therapy platforms for cancer, autoimmune,
June 20, 2024	EX-99.1	CERTIFICATE OF DESIGNATION OF PREFERENCES, RIGHTS AND LIMITATIONS SERIES A CONVERTIBLE PREFERRED STOCK COEPTIS THERAPEUTICS HOLDINGS, INC. Exhibit 99.1 CERTIFICATE OF DESIGNATION OF PREFERENCES, RIGHTS AND LIMITATIONS OF SERIES A CONVERTIBLE PREFERRED STOCK OF COEPTIS THERAPEUTICS HOLDINGS, INC. The undersigned, David Mehalick, does hereby certify that: 1. He is the Chief Executive Officer of Coeptis Therapeutics Holdings, Inc., a Delaware corporation (the “Company”). 2. The Company is authorized to issue 10,000,000 shares of preferr
May 10, 2024	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ Quarterly REPORT PURSUANT to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended March 31, 2024 or ☐ TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transaction period from to Commission File No. 001-39669 COEPTIS THE
March 26, 2024	424B3	2,150,000 shares of Common Stock Pre-Funded Warrants to Purchase up to 1,350,000 Shares of Common Stock Series A Warrants to Purchase up to 3,062,500 shares of Common Stock and Series B Warrants to Purchase up to 3,062,500 shares of Common Stock (Sha PROSPECTUS SUPPLEMENT NO. 4 Filed Pursuant to Rule 424(b)(3) (to prospectus dated June 14, 2023) Registration Statement No. 333-269782 2,150,000 shares of Common Stock Pre-Funded Warrants to Purchase up to 1,350,000 Shares of Common Stock Series A Warrants to Purchase up to 3,062,500 shares of Common Stock and Series B Warrants to Purchase up to 3,062,500 shares of Common Stock (Shares of Common S
March 26, 2024	424B3	Up to 12,080,000 shares of Common Stock PROSPECTUS SUPPLEMENT NO. 2 Filed Pursuant to Rule 424(b)(3) (to prospectus dated November 29, 2023) Registration Statement No. 333-275558 Up to 12,080,000 shares of Common Stock This prospectus supplement (the “Prospectus Supplement”) updates and supplements the prospectus dated November 29, 2023 (the “Prospectus”), which forms a part of our Registration Statement on Form S-1 (Registration No. 33
March 26, 2024	10-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Fiscal Year Ended December 31, 2023 Or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39
March 26, 2024	EX-21.1	Subsidiaries of Coeptis Therapeutics Holdings, Inc. Exhibit 21.1 Subsidiaries of Coeptis Therapeutics Holdings, Inc. Coeptis Therapeutics, Inc. Delaware Coeptis Pharmaceuticals, Inc. Delaware Coeptis Pharmaceuticals LLC Pennsylvania
March 25, 2024	10-Q/A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q/A Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q/A x Quarterly REPORT PURSUANT to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended March 31, 2023 or ☐ TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transaction period from to Commission File No. 001-39669 COEPTIS T
March 25, 2024	8-K	Non-Reliance on Previously Issued Financial Statements or a Related Audit Report or Completed Interim Review SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of Earliest Event Reported): March 19, 2024 COEPTIS THERAPEUTICS HOLDINGS, INC. (Exact name of registrant as specified in its charter) Delaware 001-39669 98-1465952 (State or other jurisdiction of incorporation) (Commission Fi
March 25, 2024	10-Q/A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q/A Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q/A x Quarterly REPORT PURSUANT to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended September 30, 2023 or ¨ TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transaction period from to Commission File No. 001-39669 COEPT
March 25, 2024	10-Q/A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q/A Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q/A x Quarterly REPORT PURSUANT to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended June 30, 2023 or ¨ TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transaction period from to Commission File No. 001-39669 COEPTIS TH
March 25, 2024	10-K/A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K/A Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K/A (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Fiscal Year Ended December 31, 2022 Or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-
February 14, 2024	SC 13G	US19207A1088 / COEPTIS THERAPEUTICS HOLDINGS INC / ARMISTICE CAPITAL, LLC Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No.
February 5, 2024	424B3	2,150,000 shares of Common Stock Pre-Funded Warrants to Purchase up to 1,350,000 Shares of Common Stock Series A Warrants to Purchase up to 3,062,500 shares of Common Stock and Series B Warrants to Purchase up to 3,062,500 shares of Common Stock (Sha PROSPECTUS SUPPLEMENT NO. 3 Filed Pursuant to Rule 424(b)(3) (to prospectus dated June 14, 2023) Registration Statement No. 333-269782 2,150,000 shares of Common Stock Pre-Funded Warrants to Purchase up to 1,350,000 Shares of Common Stock Series A Warrants to Purchase up to 3,062,500 shares of Common Stock and Series B Warrants to Purchase up to 3,062,500 shares of Common Stock (Shares of Common S
February 5, 2024	424B3	Up to 12,080,000 shares of Common Stock PROSPECTUS SUPPLEMENT NO. 1 Filed Pursuant to Rule 424(b)(3) (to prospectus dated November 29, 2023) Registration Statement No. 333-275558 Up to 12,080,000 shares of Common Stock This prospectus supplement (the “Prospectus Supplement”) updates and supplements the prospectus dated November 29, 2023 (the “Prospectus”), which forms a part of our Registration Statement on Form S-1 (Registration No. 33
February 1, 2024	8-K	Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Other Events SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of Earliest Event Reported): January 29, 2024 COEPTIS THERAPEUTICS HOLDINGS, INC. (Exact name of registrant as specified in its charter) Delaware 001-39669 98-1465952 (State or other jurisdiction of incorporation) (Commission
December 22, 2023	8-K	Submission of Matters to a Vote of Security Holders SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of Earliest Event Reported): December 20, 2023 COEPTIS THERAPEUTICS HOLDINGS, INC. (Exact name of registrant as specified in its charter) Delaware 001-39669 98-1465952 (State or other jurisdiction of incorporation) (Commission
December 18, 2023	424B3	2,150,000 shares of Common Stock Pre-Funded Warrants to Purchase up to 1,350,000 Shares of Common Stock Series A Warrants to Purchase up to 3,062,500 shares of Common Stock and Series B Warrants to Purchase up to 3,062,500 shares of Common Stock (Sha PROSPECTUS SUPPLEMENT NO. 2 Filed Pursuant to Rule 424(b)(3) (to prospectus dated June 14, 2023) Registration Statement No. 333-269782 2,150,000 shares of Common Stock Pre-Funded Warrants to Purchase up to 1,350,000 Shares of Common Stock Series A Warrants to Purchase up to 3,062,500 shares of Common Stock and Series B Warrants to Purchase up to 3,062,500 shares of Common Stock (Shares of Common S
December 5, 2023	EX-99.1	1 © 2023 Coeptis Therapeutics Holdings, Inc. All rights reserved Coeptis Therapeutics Holdings, Inc. Corporate Overview NASDAQ: COEP C10050 V5.0 December - 2023 Exhibit 99.1 1 © 2023 Coeptis Therapeutics Holdings, Inc. All rights reserved Coeptis Therapeutics Holdings, Inc. Corporate Overview NASDAQ: COEP C10050 V5.0 December - 2023 2 © 2023 Coeptis Therapeutics Holdings, Inc. All rights reserved Cautionary Note Regarding Forward - Looking Statements Certain statements in this Presentation, and statements by management or other persons acting by or on beh
December 5, 2023	8-K	SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of Earliest Event Reported): December 5, 2023 COEPTIS THERAPEUTICS HOLDINGS, SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of Earliest Event Reported): December 5, 2023 COEPTIS THERAPEUTICS HOLDINGS, INC. (Exact name of registrant as specified in its charter) Delaware 001-39669 98-1465952 (State or other jurisdiction of incorporation) (Commission
November 30, 2023	424B3	Up to 12,080,000 shares of Common Stock Table of Contents Filed Pursuant to Rule 424(b)(3) Registration Statement No. 333-275558 Up to 12,080,000 shares of Common Stock Pursuant to this prospectus, the selling stockholders identified herein (the “Selling Stockholders”) are offering on a resale basis an aggregate of up to 12,080,000 shares of common stock of Coeptis Therapeutics Holdings, Inc. (the “Company,” “we,” “us” or our”), par val
November 28, 2023	CORRESP	Coeptis Therapeutics Holdings, Inc. 105 Bradford Rd, Suite 420 Wexford, Pennsylvania 15090 Coeptis Therapeutics Holdings, Inc. 105 Bradford Rd, Suite 420 Wexford, Pennsylvania 15090 November 28, 2023 VIA EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences 100 F Street, N.E. Washington, DC 20549 Attention: Lauren S. Hammil Re: Coeptis Therapeutics Holdings, Inc. Registration Statement on Form S-1 Filed on November 15, 2023 File No. 333-27
November 17, 2023	DEF 14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Definitive Proxy State
November 15, 2023	EX-FILING FEES	Filing Fee Table Exhibit 107 Calculation of Filing Fee Tables FORM S-1 (Form Type) COEPTIS THERAPEUTICS HOLDINGS, INC.
November 15, 2023	S-1	As filed with the Securities and Exchange Commission on November 14, 2023 Table of Contents As filed with the Securities and Exchange Commission on November 14, 2023 Registration No.
November 9, 2023	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q x Quarterly REPORT PURSUANT to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended September 30, 2023 or ¨ TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transaction period from to Commission File No. 001-39669 COEPTIS
November 7, 2023	PRE 14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☒ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Definitive Proxy State
October 27, 2023	EX-99.1	Coeptis Therapeutics Announces $2 Million Private Placement Exhibit 99.1 Coeptis Therapeutics Announces $2 Million Private Placement Wexford, PA, October 24, 2023 – Coeptis Therapeutics Holdings, Inc. (NASDAQ: COEP) (“Coeptis” or “the Company”), a biopharmaceutical company developing innovative cell therapy platforms for cancer, today announced that it has entered into a definitive agreement with a single healthcare focused investor for the issuance and sa
October 27, 2023	EX-4.4	Form of Placement Agent Warrant Exhibit 4.4 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTR
October 27, 2023	EX-10.2	Registration Rights Agreement Exhibit 10.2 REGISTRATION RIGHTS AGREEMENT This Registration Rights Agreement (this “Agreement”) is made and entered into as of October 23, 2023, between Coeptis Therapeutics Holdings, Inc., a Delaware corporation (the “Company”), and each of the several purchasers signatory hereto (each such purchaser, a “Purchaser” and, collectively, the “Purchasers”). This Agreement is made pursuant to the Secu
October 27, 2023	EX-10.1	Securities Purchase Agreement Exhibit 10.1 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”) is dated as of October 23, 2023, between Coeptis Therapeutics Holdings, Inc., a Delaware corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively, the “Purchasers”). RECITALS WHEREAS, subject to
October 27, 2023	EX-4.1	Form of Pre-Funded Warrant Exhibit 4.1 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTR
October 27, 2023	EX-10.5	Form of Warrant Amendment Agreement Exhibit 10.5 October 23, 2023 Holder of Warrants to Purchase Common Stock issued on June 16, 2023. Re: Amendment to Existing Warrants Dear Holder: Reference is hereby made to the Securities Purchase Agreement, dated on or about the date hereof (the “Purchase Agreement”) between Coeptis Therapeutics Holdings, Inc. (the “Company”) and the Holder for the issuance and sale in a private placement (the
October 27, 2023	EX-4.2	Form of Series A Warrant Exhibit 4.2 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTR
October 27, 2023	8-K	Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Financial Statements and Exhibits, Other Events SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of Earliest Event Reported): October 23, 2023 COEPTIS THERAPEUTICS HOLDINGS, INC. (Exact name of registrant as specified in its charter) Delaware 001-39669 98-1465952 (State or other jurisdiction of incorporation) (Commission
October 27, 2023	EX-10.4	Form of Placement Agency Agreement Exhibit 10.4 PLACEMENT AGENCY AGREEMENT October 23, 2023 Ladenburg Thalmann & Co. Inc. 999 Vanderbilt Beach Road, Suite 200 Naples, Florida 34108 Ladies and Gentlemen: Introduction. Subject to the terms and conditions herein (this “Agreement”), Coeptis Therapeutics Holdings, Inc., a Delaware corporation (the “Company”), hereby agrees to sell up to an aggregate of $2,000,000.00 of securities of the
October 27, 2023	EX-4.3	Form of Series B Warrant Exhibit 4.3 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTR
October 13, 2023	8-K	Unregistered Sales of Equity Securities SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of Earliest Event Reported): September 29, 2023 COEPTIS THERAPEUTICS HOLDINGS, INC. (Exact name of registrant as specified in its charter) Delaware 001-39669 98-1465952 (State or other jurisdiction of incorporation) (Commissio
September 26, 2023	424B3	2,150,000 shares of Common Stock Pre-Funded Warrants to Purchase up to 1,350,000 Shares of Common Stock Series A Warrants to Purchase up to 3,062,500 shares of Common Stock and Series B Warrants to Purchase up to 3,062,500 shares of Common Stock (Sha PROSPECTUS SUPPLEMENT NO. 1 Filed Pursuant to Rule 424(b)(3) (to prospectus dated June 14, 2023) Registration Statement No. 333-269782 2,150,000 shares of Common Stock Pre-Funded Warrants to Purchase up to 1,350,000 Shares of Common Stock Series A Warrants to Purchase up to 3,062,500 shares of Common Stock and Series B Warrants to Purchase up to 3,062,500 shares of Common Stock (Shares of Common S
August 30, 2023	8-K	Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of Earliest Event Reported): August 28, 2023 COEPTIS THERAPEUTICS HOLDINGS, INC. (Exact name of registrant as specified in its charter) Delaware 001-39669 98-1465952 (State or other jurisdiction of incorporation) (Commission F
August 22, 2023	EX-10.3	Asset Purchase Agreement, dated as of August 16, 2023, by and between Coeptis Therapeutics Holdings, Inc. and Deverra Therapeutics, Inc. Exhibit 10.3 ASSET PURCHASE AGREEMENT This ASSET PURCHASE AGREEMENT (this “Agreement”) is entered into on this 16th day of August, 2023, by and between Deverra Therapeutics, Inc., a Delaware corporation (“Deverra”), and Coeptis Therapeutics Holdings, Inc., a Delaware corporation (“Coeptis”). Deverra and Coeptis may each be referred to herein individually as a “Party” and collectively as the “Parti
August 22, 2023	EX-10.1	License Agreement, dated as of August 16, 2023, by and between Coeptis Therapeutics Holdings, Inc. and Deverra Therapeutics, Inc. Exhibit 10.1 LICENSE AGREEMENT This LICENSE AGREEMENT (the “Agreement”) is made and effective as of August 16, 2023 (the “Effective Date”), by and between Deverra Therapeutics, Inc., a Delaware corporation (“Deverra”) and Coeptis Therapeutics Holdings, Inc., a Delaware limited liability company (“Licensee”) (each of Deverra and Licensee being a “Party,” and collectively, the “Parties”). BACKGROUND
August 22, 2023	EX-10.2	Sublicense Agreement, dated as of August 16, 2023, by and between Coeptis Therapeutics Holdings, Inc. and Deverra Therapeutics, Inc. Exhibit 10.2 SUBLICENSE AGREEMENT This SUBLICENSE AGREEMENT (the “Agreement”) is made and effective as of August 16, 2023 (the “Effective Date”), by and between Deverra Therapeutics, Inc., a Delaware corporation (“Deverra”) and Coeptis Therapeutics Holdings, Inc., a Delaware limited liability company (“Licensee”) (each of Deverra and Licensee being a “Party,” and collectively, the “Parties”). RECI
August 22, 2023	8-K	Entry into a Material Definitive Agreement, Financial Statements and Exhibits, Completion of Acquisition or Disposition of Assets, Other Events SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of Earliest Event Reported): August 16, 2023 COEPTIS THERAPEUTICS HOLDINGS, INC. (Exact name of registrant as specified in its charter) Delaware 001-39669 98-1465952 (State or other jurisdiction of incorporation) (Commission F
August 22, 2023	EX-99.1	Coeptis Therapeutics Completes Exclusive License for Allogeneic Immuno-Oncology Platform and Clinical Stage Assets from Deverra Therapeutics Coeptis bolsters pipeline with two Phase 1 clinical stage assets leveraging NK cell therapies in relapsed or Exhibit 99.1 Coeptis Therapeutics Completes Exclusive License for Allogeneic Immuno-Oncology Platform and Clinical Stage Assets from Deverra Therapeutics Coeptis bolsters pipeline with two Phase 1 clinical stage assets leveraging NK cell therapies in relapsed or refractory acute myeloid leukemia (AML)/high risk MDS and hospitalized respiratory infections, as well as preclinical programs for hemato
August 11, 2023	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q x Quarterly REPORT PURSUANT to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended June 30, 2023 or ¨ TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transaction period from to Commission File No. 001-39669 COEPTIS THER
June 16, 2023	EX-99.2	Coeptis Therapeutics Holdings, Inc. Announces Closing of $3.5 Million Underwritten Offering Exhibit 99.2 Coeptis Therapeutics Holdings, Inc. Announces Closing of $3.5 Million Underwritten Offering WEXFORD, Pa., June 16, 2023 - Coeptis Therapeutics Holdings, Inc. (NASDAQ: COEP) ("Coeptis" or the "Company"), a biopharmaceutical company developing innovative cell therapy platforms for cancer, today announced the closing of an underwritten offering for gross proceeds of approximately $3.5 mi
June 16, 2023	EX-4.2	Form of Pre-Funded Warrant EX-4.2 4 coeptisex0402.htm FORM OF PRE-FUNDED WARRANT Exhibit 4.2 PRE-FUNDED COMMON STOCK PURCHASE WARRANT COEPTIS THERAPEUTICS HOLDINGS, INC. Warrant Shares: Initial Exercise Date: June 16, 2023 THIS PRE-FUNDED COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and t
June 16, 2023	EX-99.1	Coeptis Therapeutics Holdings, Inc. Announces Pricing of $3.5 Million Underwritten Offering Exhibit 99.1 Coeptis Therapeutics Holdings, Inc. Announces Pricing of $3.5 Million Underwritten Offering WEXFORD, Pa., June 14, 2023 - Coeptis Therapeutics Holdings, Inc. (NASDAQ: COEP) ("Coeptis" or the "Company"), a biopharmaceutical company developing innovative cell therapy platforms for cancer, today announced the pricing of an underwritten offering for gross proceeds of approximately $3.5 mi
June 16, 2023	8-K	SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of Earliest Event Reported): June 16, 2023 COEPTIS THERAPEUTICS HOLDINGS, IN SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of Earliest Event Reported): June 16, 2023 COEPTIS THERAPEUTICS HOLDINGS, INC. (Exact name of registrant as specified in its charter) Delaware 001-39669 98-1465952 (State or other jurisdiction of incorporation) (Commission Fil
June 16, 2023	EX-4.1	Warrant Agency Agreement dated as of June 16, 2023, by and between Coeptis Therapeutics Holdings, Inc. and Continental Stock Transfer & Trust Company. Exhibit 4.1 WARRANT AGENT AGREEMENT WARRANT AGENT AGREEMENT (this “Warrant Agreement”) dated as of June 16, 2023 (the “Issuance Date”) between Coeptis Therapeutics Holdings, Inc., a Delaware corporation (the “Company”), and Continental Stock Transfer & Trust Company, a New York corporation (the “Warrant Agent”). RECITALS WHEREAS, pursuant to the terms of that certain Underwriting Agreement (“Under
June 16, 2023	EX-4.3	Form of Series A Warrant EX-4.3 5 coeptisex0403.htm FORM OF SERIES A WARRANT Exhibit 4.3 SERIES A COMMON STOCK PURCHASE WARRANT COEPTIS THERAPEUTICS HOLDINGS, INC. Warrant Shares: Initial Exercise Date: December 16, 2023 THIS SERIES A COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the
June 16, 2023	EX-1.1	Underwriter Agreement Exhibit 1.1 2,150,000 shares of Common Stock Pre-Funded Warrants to Purchase up to 1,350,000 Shares of Common Stock Series A Warrants to Purchase up to 3,062,500 shares of Common Stock and Series B Warrants to Purchase up to 3,062,500 shares of Common Stock (Shares of Common Stock underlying the Pre-Funded Warrants, Series A Warrants and Series B Warrants) OF COEPTIS THERAPEUTICS HOLDINGS, INC. UN
June 16, 2023	EX-4.4	Form of Series A Warrant EX-4.4 6 coeptisex0404.htm FORM OF SERIES B WARRANT Exhibit 4.4 SERIES B COMMON STOCK PURCHASE WARRANT COEPTIS THERAPEUTICS HOLDINGS, INC. Warrant Shares: Initial Exercise Date: December 16, 2023 THIS SERIES B COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the
June 15, 2023	424B4	2,150,000 shares of Common Stock Pre-Funded Warrants to Purchase up to 1,350,000 Shares of Common Stock Series A Warrants to Purchase up to 3,062,500 shares of Common Stock and Series B Warrants to Purchase up to 3,062,500 shares of Common Stock (Sha Table of Contents Filed Pursuant to Rule 424(b)(4) File Number 333-269782 2,150,000 shares of Common Stock Pre-Funded Warrants to Purchase up to 1,350,000 Shares of Common Stock Series A Warrants to Purchase up to 3,062,500 shares of Common Stock and Series B Warrants to Purchase up to 3,062,500 shares of Common Stock (Shares of Common Stock underlying the Pre-Funded Warrants, Series A Warrants and Series B Warrants) This prospectus (“prospectus”) relates to the offering of 2,150,000 shares of common stock, par value $0.
June 14, 2023	EX-FILING FEES	Filing Fee Table Exhibit 107 Calculation of Filing Fee Tables FORM S-1 (Form Type) COEPTIS THERAPEUTICS HOLDINGS, INC.
June 14, 2023	S-1MEF	As filed with the Securities and Exchange Commission on June 14, 2023 As filed with the Securities and Exchange Commission on June 14, 2023 Registration No.
June 13, 2023	EX-4.2	Form of Series B Warrant Exhibit 4.2 SERIES B COMMON STOCK PURCHASE WARRANT COEPTIS THERAPEUTICS HOLDINGS, INC. Warrant Shares: Initial Exercise Date: June , 2023 THIS SERIES B COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after
June 13, 2023	EX-FILING FEES	Filing Fee Table Exhibit 107 Calculation of Filing Fee Tables FORM S-1 (Form Type) COEPTIS THERAPEUTICS HOLDINGS, INC.
June 13, 2023	S-1MEF	As filed with the Securities and Exchange Commission on June 13, 2023 As filed with the Securities and Exchange Commission on June 13, 2023 Registration No.
June 13, 2023	EX-4.1	Form of Series A Warrant Exhibit 4.1 SERIES A COMMON STOCK PURCHASE WARRANT COEPTIS THERAPEUTICS HOLDINGS, INC. Warrant Shares: Initial Exercise Date: June , 2023 THIS SERIES A COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after
June 13, 2023	EX-FILING FEES	Filing Fee Table Exhibit 107 Calculation of Filing Fee Tables FORM S-1 (Form Type) COEPTIS THERAPEUTICS HOLDINGS, INC.
June 13, 2023	S-1/A	As filed with the Securities and Exchange Commission on June 12, 2023 Table of Contents As filed with the Securities and Exchange Commission on June 12, 2023 Registration No.
June 13, 2023	EX-1.1	Underwriting Agreement dated [______], 2023, by and between Ladenburg Thalmann & Co. Inc. and Coeptis Therapeutics Holdings, Inc. EX-1.1 2 coeptisex0110.htm UNDERWRITING AGREEMENT DATED [], 2023, BY AND BETWEEN LADENBURG THALMANN & CO. INC. AND COEPTIS THERAPEUTICS HOLDINGS, INC. Exhibit 1.1 [] shares of Common Stock and Accompanying Series A Warrants to Purchase [] Shares of Common Stock and Series B Warrants to Purchase [] Shares of Common Stock Pre-Funded Warrants to Purchase [] shares of Common Stock and Accompanying Ser
June 12, 2023	CORRESP	Coeptis Therapeutics Holdings, Inc. 105 Bradford Rd, Suite 420 Wexford, Pennsylvania 15090 Coeptis Therapeutics Holdings, Inc. 105 Bradford Rd, Suite 420 Wexford, Pennsylvania 15090 June 12, 2023 VIA EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, DC 20549 Attention: Timothy Buchmiller Re: Coeptis Therapeutics Holdings, Inc. Registration Statement on Form S-1 File No. 333-260782 Ladies and Gentlemen: Pursuant to Rule 461 of th
June 12, 2023	CORRESP	[Remainder of Page Intentionally Left Blank] June 12, 2023 VIA EDGAR Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.
June 9, 2023	8-K	Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Financial Statements and Exhibits, Other Events SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of Earliest Event Reported): June 9, 2023 COEPTIS THERAPEUTICS HOLDINGS, INC. (Exact name of registrant as specified in its charter) Delaware 001-39669 98-1465952 (State or other jurisdiction of incorporation) (Commission File
June 9, 2023	EX-99.1	Coeptis Therapeutics Receives Approval to Transfer to The Nasdaq Capital Market Trading to commence effective with the open of business on June 13, 2023 Exhibit 99.1 Coeptis Therapeutics Receives Approval to Transfer to The Nasdaq Capital Market Trading to commence effective with the open of business on June 13, 2023 Wexford, PA, June 9, 2023 – Coeptis Therapeutics Holdings, Inc. (NASDAQ: COEP) (“Coeptis” or the “Company”), a biopharmaceutical company developing innovative cell therapy platforms for cancer, announced today that it received approva
June 7, 2023	EX-FILING FEES	Filing Fee Table Exhibit 107 Calculation of Filing Fee Tables FORM S-1 (Form Type) COEPTIS THERAPEUTICS HOLDINGS, INC.
June 7, 2023	EX-4.1	Form of Common Stock Purchase Warrant EX-4.1 3 coeptisex0401.htm COMMON STOCK PURCHASE WARRANT Exhibit 4.1 COMMON STOCK PURCHASE WARRANT COEPTIS THERAPEUTICS HOLDINGS, INC. Warrant Shares: Initial Exercise Date: June , 2023 THIS COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereina
June 7, 2023	EX-4.3	Form of Pre-Funded Warrant Exhibit 4.3 PRE-FUNDED COMMON STOCK PURCHASE WARRANT COEPTIS THERAPEUTICS HOLDINGS, INC. Warrant Shares: Initial Exercise Date: June , 2023 THIS PRE-FUNDED COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or a
June 7, 2023	S-1/A	As filed with the Securities and Exchange Commission on June 6, 2023 As filed with the Securities and Exchange Commission on June 6, 2023 Registration No.
June 7, 2023	EX-1.1	Underwriting Agreement dated June __, 2023, by and between Ladenburg Thalmann & Co. Inc. and Coeptis Therapeutics Holdings, Inc. Exhibit 1.1 shares of Common Stock Pre-Funded Warrants to Purchase shares of Common Stock Warrants to Purchase Shares of Common Stock ( shares of Common Stock issuable upon exercise of the Pre-Funded Warrants and shares of Common Stock issuable upon exercise of the Warrants) OF COEPTIS THERAPEUTICS HOLDINGS, INC. UNDERWRITING AGREEMENT June , 2023 Ladenburg Thalmann & Co. Inc. As the Representativ
June 7, 2023	EX-4.2	Form of Underwriter Warrant Exhibit 4.2 UNDERWRITER COMMON STOCK PURCHASE WARRANT COEPTIS THERAPEUTICS HOLDINGS, INC. Warrant Shares: [·] Issuance Date: June[·], 2023 THIS UNDERWRITER COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, Ladenburg Thalmann & Co. Inc. or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter
June 6, 2023	EX-99.1	1 © 2023 Coeptis Therapeutics Holdings, Inc. All rights reserved Coeptis Therapeutics Holdings, Inc. Corporate Overview NASDAQ: COEP C10050 V4.0 18 - May 2023 Exhibit 99.1 1 © 2023 Coeptis Therapeutics Holdings, Inc. All rights reserved Coeptis Therapeutics Holdings, Inc. Corporate Overview NASDAQ: COEP C10050 V4.0 18 - May 2023 1 2 © 2023 Coeptis Therapeutics Holdings, Inc. All rights reserved Cautionary Note Regarding Forward - Looking Statements Certain statements in this Presentation, and statements by management or other persons acting by or on beh
June 6, 2023	8-K	SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of Earliest Event Reported): June 5, 2023 COEPTIS THERAPEUTICS HOLDINGS, INC SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of Earliest Event Reported): June 5, 2023 COEPTIS THERAPEUTICS HOLDINGS, INC. (Exact name of registrant as specified in its charter) Delaware 001-39669 98-1465952 (State or other jurisdiction of incorporation) (Commission File
May 31, 2023	S-1/A	As filed with the Securities and Exchange Commission on May 31, 2023 Table of Contents As filed with the Securities and Exchange Commission on May 31, 2023 Registration No.
May 31, 2023	EX-FILING FEES	Filing Fee Table Exhibit 107 Calculation of Filing Fee Tables FORM S-1 (Form Type) COEPTIS THERAPEUTICS HOLDINGS, INC.
May 17, 2023	8-K	SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of Earliest Event Reported): May 17, 2023 COEPTIS THERAPEUTICS HOLDINGS, INC SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of Earliest Event Reported): May 17, 2023 COEPTIS THERAPEUTICS HOLDINGS, INC. (Exact name of registrant as specified in its charter) Delaware 001-39669 98-1465952 (State or other jurisdiction of incorporation) (Commission File
May 17, 2023	EX-99.1	Coeptis Therapeutics Appoints Brian Cogley as Chief Financial Officer 15-year accounting and finance career spans several sectors including life sciences and underscores financial leadership abilities Exhibit 99.1 Coeptis Therapeutics Appoints Brian Cogley as Chief Financial Officer 15-year accounting and finance career spans several sectors including life sciences and underscores financial leadership abilities Wexford, PA, May 17, 2023 – Coeptis Therapeutics Holdings, Inc. (NASDAQ: COEP) (“Coeptis” or the “Company”), a biopharmaceutical company developing innovative cell therapy platforms for
May 15, 2023	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q x Quarterly REPORT PURSUANT to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended March 31, 2023 or ☐ TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transaction period from to Commission File No. 001-39669 COEPTIS THE
April 27, 2023	S-1/A	As filed with the Securities and Exchange Commission on April 26, 2023 Table of Contents As filed with the Securities and Exchange Commission on April 26, 2023 Registration No.
April 27, 2023	EX-FILING FEES	Filing Fee Table Exhibit 107 Calculation of Filing Fee Tables FORM S-1 REGISTRATION STATEMENT (Form Type) COEPTIS THERAPEUTICS HOLDINGS, INC.
March 29, 2023	EX-21.1	Subsidiaries of Coeptis Therapeutics Holdings, Inc. Exhibit 21.1 Subsidiaries of Coeptis Therapeutics Holdings, Inc. Coeptis Therapeutics, Inc. Delaware Coeptis Pharmaceuticals, Inc. Delaware Coeptis Pharmaceuticals LLC Pennsylvania
March 29, 2023	10-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Fiscal Year Ended December 31, 2022 Or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39
February 15, 2023	EX-99.1	JOINT FILING AGREEMENT EX-99.1 CUSIP No. 19207A108 SCHEDULE 13G Page 11 of 11 Pages EXHIBIT 1 JOINT FILING AGREEMENT The undersigned hereby agree that the statement on Schedule 13G with respect to the common stock of Coeptis Therapeutics Holdings, Inc. dated as of February 14, 2023 is, and any amendments thereto (including amendments on Schedule 13D) signed by each of the undersigned shall be, filed on behalf of each of
February 15, 2023	SC 13G/A	US19207A1088 / COEPTIS THERAPEUTICS HOLDINGS INC / Harraden Circle Investments, LLC - SC 13G/A Passive Investment SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* Coeptis Therapeutics Holdings, Inc.** (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 19207A108 (CUSIP Number) December 31, 2022 (Date of Event Which Requires Filing of this Statement) Check the appropri
February 14, 2023	EX-21.1	Subsidiaries of Coeptis Therapeutics Holdings, Inc. EX-21.1 2 coeptisex2101.htm SUBSIDIARIES OF COEPTIS THERAPEUTICS HOLDINGS, INC. Exhibit 21.1 Subsidiaries of Coeptis Therapeutics Holdings, Inc. Coeptis Therapeutics, Inc. Delaware Coeptis Pharmaceuticals, Inc. Delaware Coeptis Pharmaceuticals LLC Pennsylvania
February 14, 2023	EX-FILING FEES	Filing Fee Table Exhibit 107 Calculation of Filing Fee Tables FORM S-1 REGISTRATION STATEMENT (Form Type) COEPTIS THERAPEUTICS HOLDINGS, INC.
February 14, 2023	S-1	As filed with the Securities and Exchange Commission on February 14, 2023 Table of Contents As filed with the Securities and Exchange Commission on February 14, 2023 Registration No.
February 6, 2023	SC 13G/A	US19207A1088 / COEPTIS THERAPEUTICS HOLDINGS INC / Hudson Bay Capital Management LP - BHSE 13GA Passive Investment SC 13G/A 1 bhse13ga.htm BHSE 13GA SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No.)* Coeptis Therapeutics Holdings, Inc. (f/k/a Bull Horn Holdings Corp.) (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 19207A108 (CUSIP Number) December 31, 2022 (Date of Event Which Requires Fili
January 31, 2023	EX-99.1	Coeptis Therapeutics Enters into Sponsored Research Agreement with the University of Pittsburgh to Advance SNAP-CAR Development Program Coeptis to collaborate with the University of Pittsburgh to expand pre-clinical development of SNAP-CAR T cells ta Exhibit 99.1 Coeptis Therapeutics Enters into Sponsored Research Agreement with the University of Pittsburgh to Advance SNAP-CAR Development Program Coeptis to collaborate with the University of Pittsburgh to expand pre-clinical development of SNAP-CAR T cells targeting HER2-positive cancers Wexford, PA, January 31, 2023 – Coeptis Therapeutics Holdings, Inc. (NASDAQ: COEP) (“Coeptis” or “the Compa
January 31, 2023	8-K	Financial Statements and Exhibits, Other Events SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of Earliest Event Reported): January 31, 2023 COEPTIS THERAPEUTICS HOLDINGS, INC. (Exact name of registrant as specified in its charter) Delaware 001-39669 98-1465952 (State or other jurisdiction of incorporation) (Commission
December 29, 2022	8-K	Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of Earliest Event Reported): December 22, 2022 COEPTIS THERAPEUTICS HOLDINGS, INC. (Exact name of registrant as specified in its charter) Delaware 001-39669 98-1465952 (State or other jurisdiction of incorporation) (Commission
November 18, 2022	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2022 ☐ TRANSITION REPO UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2022 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number. 001-39669 COEPT
November 14, 2022	NT 10-Q	UNITED STATES UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 12b-25 NOTIFICATION OF LATE FILING (Check one): o Form 10-K o Form 20-F o Form 11-K x Form 10-Q o Form 10-D o Form N-SAR o Form N-CSR For Period Ended: September 30, 2022 o Transition Report on Form 10-K o Transition Report on Form 20-F o Transition Report on Form 11-K o Transition Report on Form 10-Q o Transition Report on Form N-SAR For the Transition Period Ended: Read Instruction (on back page) Before Preparing Form.
November 7, 2022	EX-99.3	JOINT FILING AGREEMENT Exhibit 99.3 JOINT FILING AGREEMENT In accordance with Rule 13d-1(k) under the Securities Exchange Act of 1934, as amended, the undersigned agree to the joint filing on behalf of each of them of a Statement on Schedule 13D (including any and all amendments thereto) with respect to the shares of common stock, $0.0001 par value per share, of Coeptis Therapeutics Holdings, Inc., and further agree tha
November 7, 2022	SC 13G/A	BHSE / Bull Horn Holdings Corp. / Lisa Pharma, LLC - AMENDMENT 5 Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G NFORMATION STATEMENT PURSUANT TO RULES 13d-1 AND 13d-2 UNDER THE SECURITIES EXCHANGE ACT OF 1934 (AMENDMENT N0. 5)1 Coeptis Therapeutics Holdings, Inc. (Name of Issuer) Common Shares, $0.0001 par value per share (Title of Class of Securities) 19207A108 (CUSIP Number) October 28, 2022 (Date of Event Which Requires
November 7, 2022	SC 13G/A	BHSE / Bull Horn Holdings Corp. / Lena Pharma, LLC - AMENDMENT 5 Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G INFORMATION STATEMENT PURSUANT TO RULES 13d-1 AND 13d-2 UNDER THE SECURITIES EXCHANGE ACT OF 1934 (AMENDMENT N0. 5)1 Coeptis Therapeutics Holdings, Inc. (Name of Issuer) Common Shares, $0.0001 par value per share (Title of Class of Securities) 19207A108 (CUSIP Number) October 28, 2022 (Date of Event Which Requires
November 7, 2022	SC 13D	BHSE / Bull Horn Holdings Corp. / Bull Horn Holdings Sponsor LLC - SCHEDULE 13D Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. )* COEPTIS THERAPEUTICS HOLDINGS, INC. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 19207A108 (CUSIP Number) Bull Horn Holdings Sponsor LLC 801 S. Pointe Drive, Suite TH-1 Miami Beach, Florida 33139 with a copy to
November 3, 2022	EX-21.1	Subsidiaries of Coeptis Therapeutics Holdings, Inc. Exhibit 21.1 Subsidiaries of Coeptis Therapeutics Holdings, Inc. Coeptis Therapeutics, Inc. Delaware Coeptis Pharmaceuticals, Inc. Delaware Coeptis Pharmaceuticals LLC Pennsylvania
November 3, 2022	EX-2.2	Certificate of Merger as filed with the Delaware Secretary of State effective October 28, 2022 Exhibit 2.2 CERTIFICATE OF MERGER OF BH Merger Sub, Inc. WITH AND INTO CoEPtis THERAPEUTICS, Inc. Pursuant to Title 8, Section 251(a) of the Delaware General Corporation Law (the ?DGCL?), the undersigned corporation executed the following Certificate of Merger: FIRST: The name and state of incorporation of each of the constituent corporations (the ?Constituent Corporations?) are: Name: State of In
November 3, 2022	EX-99.4	Coeptis Therapeutics, Inc. Announces Closing of Business Combination with Bull Horn Holdings Corp. Combined company to operate as Coeptis Therapeutics Holdings, Inc. and commence trading on The Nasdaq Global Market under Ticker Symbol “COEP” Exhibit 99.4 Coeptis Therapeutics, Inc. Announces Closing of Business Combination with Bull Horn Holdings Corp. Combined company to operate as Coeptis Therapeutics Holdings, Inc. and commence trading on The Nasdaq Global Market under Ticker Symbol ?COEP? WEXFORD, PA and MIAMI, FL, October 31, 2022 ? Coeptis Therapeutics, Inc. (?Coeptis?), a biopharmaceutical company developing innovative cell ther
November 3, 2022	EX-99.3	1 © 2022 Coeptis Therapeutics, Inc. All rights reserved Coeptis Therapeutics Holdings, Inc. Corporate Overview NASDAQ: COEP Exhibit 99.3 1 ? 2022 Coeptis Therapeutics, Inc. All rights reserved Coeptis Therapeutics Holdings, Inc. Corporate Overview NASDAQ: COEP 2 ? 2022 Coeptis Therapeutics, Inc. All rights reserved Cautionary Note Regarding Forward - Looking Statements Certain statements in this Presentation, and statements by management or other persons acting by or on behalf of Coeptis made in connection with this Pr
November 3, 2022	8-K	Regulation FD Disclosure, Changes in Control of Registrant, Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Change in Shell Company Status, Unregistered Sales of Equity Securities, Financial Statements and Exhibits, Completion of Acquisition or Disposition of Assets, Other Events Table of Contents SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of Earliest Event Reported): October 28, 2022 COEPTIS THERAPEUTICS HOLDINGS, INC. (Exact name of registrant as specified in its charter) Delaware 001-39669 98-1465952 (State or other jurisdiction of incorpora
November 3, 2022	EX-3.1	Amended and Restated Certificate of Incorporation of Coeptis Therapeutics Holdings, Inc. Exhibit 3.1 AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF BULL HORN HOLDINGS CORP. (Pursuant to Sections 242 and 245 of the General Corporation Law of the State of Delaware) Bull Horn Holdings Corp. (the ?Corporation?), a corporation organized and existing under and by virtue of the provisions of the General Corporation Law of the State of Delaware (the ?General Corporation Law?); DOES HERE
November 3, 2022	EX-99.5	Coeptis Therapeutics Holdings Expands Board of Directors with New Appointments New directors join Coeptis’ Board following completion of merger with Bull Horn Holdings and advancement to Nasdaq Exhibit 99.5 Coeptis Therapeutics Holdings Expands Board of Directors with New Appointments New directors join Coeptis? Board following completion of merger with Bull Horn Holdings and advancement to Nasdaq Wexford, PA, Nov. 2, 2022 ? Coeptis Therapeutics Holdings, Inc. (NASDAQ: COEP) (the ?Company?), a biopharmaceutical company developing innovative cell therapy platforms for cancer, today announ
November 3, 2022	EX-3.3	Amended and Restated Bylaws of Coeptis Therapeutics Holdings, Inc. Exhibit 3.3 AMENDED AND RESTATED BYLAWS OF BULL HORN HOLDINGS CORP. (and, once renamed, COEPTIS THERAPEUTICS HOLDINGS, INC.) ARTICLE I Meeting of Stockholders 1. Annual Meetings. If required by applicable law, an annual meeting of stockholders shall be held for the election of directors at such date, time and place, if any, either within or without the State of Delaware, as may be designated by re
November 3, 2022	EX-99.1	INDEX TO FINANCIAL STATEMENTS Coeptis Therapeutics, Inc. EX-99.1 8 coeptisex9901.htm AUDITED FINANCIAL STATEMENTS OF COEPTIS THERAPEUTICS, INC. Exhibit 99.1 INDEX TO FINANCIAL STATEMENTS Coeptis Therapeutics, Inc. Page Report of Independent Registered Public Accounting Firm F-2 Consolidated Balance Sheets as of December 31, 2021 and December 31, 2020 F-4 Consolidated Statements of Operations and Comprehensive Loss for the years ended December 31, 2021 a
November 3, 2022	EX-4.1	2022 Equity Incentive Plan Exhibit 4.1 COEPTIS THERAPEUTICS HOLDINGS INC. 2022 EQUITY INCENTIVE PLAN 1. GENERAL. (a) Plan Purpose. The Company, by means of the Plan, seeks to secure and retain the services of Employees, Directors and Consultants, to provide incentives for such persons to exert maximum efforts for the success of the Company and any Affiliate and to provide a means by which such persons may be given an opport
November 3, 2022	EX-99.2	NOTES TO UNAUDITED PRO FORMA CONDENSED COMBINED FINANCIAL STATEMENTS Exhibit 99.2 Additional Transaction Accounting Pro Forma Adjustments Combined (Assuming (Assuming Coeptis Bullhorn Actual Actual (Historical) (Historical) Redemptions) Redemptions) Assets Current assets: Cash and cash equivalents $ 2,378 $ 84 (1) $ 3,829 (3) $ 6,291 (4) (3,466 ) $ (3,466 ) (7) (574 ) $ (574 ) (7) 574 $ 574 (8) 6,638 $ 6,638 (2) (374 ) $ (374 ) Prepaid expenses and other current as
October 26, 2022	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): October 26, 2022 BULL HORN HOLDIN UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): October 26, 2022 BULL HORN HOLDINGS CORP. (Exact name of registrant as specified in its charter) British Virgin Islands 001-39669 98-1465952 (State or other jurisdiction of incorporat
October 26, 2022	425	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): October 26, 2022 BULL HORN HOLDIN 425 1 ea167617-8k425bullhorn.htm CURRENT REPORT UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): October 26, 2022 BULL HORN HOLDINGS CORP. (Exact name of registrant as specified in its charter) British Virgin Islands 001-39669 98-14
October 11, 2022	DEF 14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Definitive Proxy State
September 30, 2022	424B3	BULL HORN HOLDINGS CORP. 801 S. Pointe Drive, Suite TH-1 Miami Beach, Florida 33139 Prospectus Filed Pursuant to Rule 424(b)(3) Registration No. 333-265206 BULL HORN HOLDINGS CORP. 801 S. Pointe Drive, Suite TH-1 Miami Beach, Florida 33139 To the Shareholders of Bull Horn Holdings Corp.: On behalf of the board of directors of Bull Horn Holdings Corp. (?Bull Horn?), we are pleased to enclose the proxy statement/prospectus relating to the proposed merger (the ?Business Combination?
September 30, 2022	S-4/A	As filed with the United States Securities and Exchange Commission on September 29, 2022 As filed with the United States Securities and Exchange Commission on September 29, 2022 Registration No.
September 30, 2022	PRE 14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Definitive Proxy State
September 29, 2022	CORRESP	Bull Horn Holdings Corp. 801 S. Pointe Drive, Suite TH-1 Miami Beach, Florida 33139 Bull Horn Holdings Corp. 801 S. Pointe Drive, Suite TH-1 Miami Beach, Florida 33139 VIA EDGAR September 29, 2022 U.S. Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences 100 F Street, NE Washington, D.C. 20549 Attention: Joshua Gorsky Tim Buchmiller Nudrat Salik Tracey Houser Re: Bull Horn Holdings Corp. Amendment No. 6 to Registration Statement on Form S-4 (
September 26, 2022	S-4/A	Form of Interim Certificate of Incorporation of the Registrant, to become effective upon the Domestication (included as Annex B to the proxy statement/prospectus). As filed with the United States Securities and Exchange Commission on September 26, 2022 Registration No.
September 26, 2022	CORRESP	Bull Horn Holdings Corp. 801 S. Pointe Drive, Suite TH-1 Miami Beach, Florida 33139 Bull Horn Holdings Corp. 801 S. Pointe Drive, Suite TH-1 Miami Beach, Florida 33139 VIA EDGAR September 26, 2022 U.S. Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences 100 F Street, NE Washington, D.C. 20549 Attention: Joshua Gorsky Tim Buchmiller Nudrat Salik Tracey Houser Re: Bull Horn Holdings Corp. Amendment No. 4 to Registration Statement on Form S-4 F
September 12, 2022	S-4/A	As filed with the United States Securities and Exchange Commission on September 12, 2022 As filed with the United States Securities and Exchange Commission on September 12, 2022 Registration No.
September 12, 2022	CORRESP	Bull Horn Holdings Corp. 801 S. Pointe Drive, Suite TH-1 Miami Beach, Florida 33139 CORRESP 1 filename1.htm Bull Horn Holdings Corp. 801 S. Pointe Drive, Suite TH-1 Miami Beach, Florida 33139 VIA EDGAR September 12, 2022 U.S. Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences 100 F Street, NE Washington, D.C. 20549 Attention: Joshua Gorsky Tim Buchmiller Nudrat Salik Tracey Houser Re: Bull Horn Holdings Corp. Amendment No. 3 to Registration
September 12, 2022	EX-3.2	Form of Interim Certificate of Incorporation of the Registrant, to become effective upon the Domestication (included as Annex B to the proxy statement/prospectus). Exhibit 3.2 CERTIFICATE OF INCORPORATION OF BULL HORN HOLDINGS CORP. Article I. NAME OF CORPORATION Section 1.01 The name of the corporation is Bull Horn Holdings Corp. (the ?Corporation?). Article II. PURPOSE Section 2.01 The purpose of the Corporation is to engage in any lawful act or activity for which corporations may be organized under the Delaware General Corporation Law (the ?DGCL?). In add
August 22, 2022	CORRESP	Bull Horn Holdings Corp. 801 S. Pointe Drive, Suite TH-1 Miami Beach, Florida 33139 CORRESP 1 filename1.htm Bull Horn Holdings Corp. 801 S. Pointe Drive, Suite TH-1 Miami Beach, Florida 33139 VIA EDGAR August 22, 2022 U.S. Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences 100 F Street, NE Washington, D.C. 20549 Attention: Joshua Gorsky Tim Buchmiller Nudrat Salik Tracey Houser Re: Bull Horn Holdings Corp. Amendment No. 2 to Registration St
August 22, 2022	S-4/A	As filed with the United States Securities and Exchange Commission on August 22, 2022 As filed with the United States Securities and Exchange Commission on August 22, 2022 Registration No.
August 9, 2022	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2022 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number. 001-39669 BULL HORN
July 28, 2022	EX-21.1	List of Subsidiaries. Exhibit 21.1 Entity Jurisdiction BH Merger Sub Inc. Delaware
July 28, 2022	S-4/A	Form of Amended and Restated Bylaws of the Registrant, to become effective upon the Business Combination (included as Annex D to the proxy statement/prospectus). As filed with the United States Securities and Exchange Commission on July 27, 2022 Registration No.
July 27, 2022	CORRESP	Bull Horn Holdings Corp. 801 S. Pointe Drive, Suite TH-1 Miami Beach, Florida 33139 CORRESP 1 filename1.htm Bull Horn Holdings Corp. 801 S. Pointe Drive, Suite TH-1 Miami Beach, Florida 33139 VIA EDGAR July 27, 2022 U.S. Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences 100 F Street, NE Washington, D.C. 20549 Attention: Joshua Gorsky Tim Buchmiller Nudrat Salik Tracey Houser Re: Bull Horn Holdings Corp. Amendment No. 1 to Registration Stat
July 6, 2022	EX-99.6	Consent of Tara Maria DeSilva to be named as a Director. Exhibit 99.6 Consent to be Named as a Director Nominee In connection with the filing by Bull Horn Holdings Corp. of the Registration Statement on Form S-4 with the Securities and Exchange Commission under the Securities Act of 1933, as amended (the ?Securities Act?), I hereby consent, pursuant to Rule 438 of the Securities Act, to being named as a nominee to the board of directors of Bull Horn Hol
July 6, 2022	425	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): July 6, 2022 BULL HORN HOLDINGS C UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): July 6, 2022 BULL HORN HOLDINGS CORP. (Exact name of registrant as specified in its charter) British Virgin Islands 001-39669 98-1465952 (State or other jurisdiction of incorporation)
July 6, 2022	EX-99.1	1 © 2022 Coeptis Therapeutics, Inc. All rights reserved Coeptis Therapeutics, Inc. Corporate Overview 2 © 2022 Coeptis Therapeutics, Inc. All rights reserved Important Legal Disclaimers This presentation (the “Presentation”) has been prepared for inf Exhibit 99.1 1 ? 2022 Coeptis Therapeutics, Inc. All rights reserved Coeptis Therapeutics, Inc. Corporate Overview 2 ? 2022 Coeptis Therapeutics, Inc. All rights reserved Important Legal Disclaimers This presentation (the ?Presentation?) has been prepared for informational purposes only to assist interested parties in eval uat ing an investment in connection with a proposed business combination (t
July 6, 2022	8-K	Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): July 6, 2022 BULL HORN HOLDINGS CORP. (Exact name of registrant as specified in its charter) British Virgin Islands 001-39669 98-1465952 (State or other jurisdiction of incorporation)
July 6, 2022	S-4/A	As filed with the United States Securities and Exchange Commission on July 5, 2022 As filed with the United States Securities and Exchange Commission on July 5, 2022 Registration No.
July 6, 2022	EX-99.1	1 © 2022 Coeptis Therapeutics, Inc. All rights reserved Coeptis Therapeutics, Inc. Corporate Overview 2 © 2022 Coeptis Therapeutics, Inc. All rights reserved Important Legal Disclaimers This presentation (the “Presentation”) has been prepared for inf Exhibit 99.1 1 ? 2022 Coeptis Therapeutics, Inc. All rights reserved Coeptis Therapeutics, Inc. Corporate Overview 2 ? 2022 Coeptis Therapeutics, Inc. All rights reserved Important Legal Disclaimers This presentation (the ?Presentation?) has been prepared for informational purposes only to assist interested parties in eval uat ing an investment in connection with a proposed business combination (t
July 6, 2022	EX-99.7	Consent of Philippe Deschamps to be named as a Director. Exhibit 99.7 Consent to be Named as a Director Nominee In connection with the filing by Bull Horn Holdings Corp. of the Registration Statement on Form S-4 with the Securities and Exchange Commission under the Securities Act of 1933, as amended (the ?Securities Act?), I hereby consent, pursuant to Rule 438 of the Securities Act, to being named as a nominee to the board of directors of Bull Horn Hol
July 6, 2022	EX-99.1	Form of Proxy Card for Shareholders. Exhibit 99.1 PROXY CARD BULL HORN HOLDINGS CORP. 801 S. Pointe Drive, Suite TH-1 Miami Beach, Florida 33139 EXTRAORDINARY GENERAL MEETING OF SHAREHOLDERS [ ], 2022 YOUR VOTE IS IMPORTANT BULL HORN HOLDINGS CORP. THIS PROXY IS SOLICITED BY THE BOARD OF DIRECTORS FOR THE EXTRAORDINARY GENERAL MEETING OF SHAREHOLDERS TO BE HELD ON [ ], 2022 The undersigned, revoking any previous proxies relating to t
July 6, 2022	EX-99.3	Consent of Vantage Point. Exhibit 99.3 Consent of Vantage Point Advisors, Inc. We hereby consent to (i) the inclusion of our opinion letter, dated April 18, 2022, to the Board of Directors of Bull Horn Holdings Corp. as Annex G to the Proxy Statement/Prospectus which forms a part of the Registration Statement on Form S-4 related to the proposed merger with Coeptis Therapeutics, Inc. and (ii) the references to such opinion
July 6, 2022	EX-99.9	Consent of Gene Salkind to be named as a Director. Exhibit 99.9 Consent to be Named as a Director Nominee In connection with the filing by Bull Horn Holdings Corp. of the Registration Statement on Form S-4 with the Securities and Exchange Commission under the Securities Act of 1933, as amended (the “Securities Act”), I hereby consent, pursuant to Rule 438 of the Securities Act, to being named as a nominee to the board of directors of Bull Horn Hol
July 6, 2022	EX-99.8	Consent of Christopher Cochran to be named as a Director. Exhibit 99.8 Consent to be Named as a Director Nominee In connection with the filing by Bull Horn Holdings Corp. of the Registration Statement on Form S-4 with the Securities and Exchange Commission under the Securities Act of 1933, as amended (the ?Securities Act?), I hereby consent, pursuant to Rule 438 of the Securities Act, to being named as a nominee to the board of directors of Bull Horn Hol
July 5, 2022	CORRESP	Bull Horn Holdings Corp. 801 S. Pointe Drive, Suite TH-1 Miami Beach, Florida 33139 CORRESP 1 filename1.htm Bull Horn Holdings Corp. 801 S. Pointe Drive, Suite TH-1 Miami Beach, Florida 33139 VIA EDGAR July 5, 2022 U.S. Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences 100 F Street, NE Washington, D.C. 20549 Attention: Joshua Gorsky Tim Buchmiller Nudrat Salik Tracey Houser Re: Bull Horn Holdings Corp. Registration Statement on Form S-4 Fi
May 25, 2022	EX-99.3	Consent of Vantage Point. Exhibit 99.3 Consent of Vantage Point Advisors, Inc. We hereby consent to (i) the inclusion of our opinion letter, dated April 18, 2022, to the Board of Directors of Bull Horn Holdings Corp. as Annex G to the Proxy Statement/Prospectus which forms a part of the Registration Statement on Form S-4 related to the proposed merger with Coeptis Therapeutics, Inc. and (ii) the references to such opinion
May 25, 2022	S-4	Power of Attorney (contained on the signature page to the initial filing this registration statement). As filed with the United States Securities and Exchange Commission on May 25, 2022 Registration No.
May 25, 2022	EX-FILING FEES	Calculation of Filing Fees Table Exhibit 107 Calculation of Filing Fee Tables Form S-4 (Form Type) Bull Horn Holdings Corp.
May 25, 2022	EX-99.5	Consent of Daniel Yerace to be named as a Director. Exhibit 99.5 Consent to be Named as a Director Nominee In connection with the filing by Bull Horn Holdings Corp. of the Registration Statement on Form S-4 with the Securities and Exchange Commission under the Securities Act of 1933, as amended (the ?Securities Act?), I hereby consent, pursuant to Rule 438 of the Securities Act, to being named as a nominee to the board of directors of Bull Horn Hol
May 25, 2022	EX-99.4	Consent of David Mehalick to be named as a Director. Exhibit 99.4 Consent to be Named as a Director Nominee In connection with the filing by Bull Horn Holdings Corp. of the Registration Statement on Form S-4 with the Securities and Exchange Commission under the Securities Act of 1933, as amended (the ?Securities Act?), I hereby consent, pursuant to Rule 438 of the Securities Act, to being named as a nominee to the board of directors of Bull Horn Hol
May 20, 2022	8-K	Entry into a Material Definitive Agreement, Financial Statements and Exhibits, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant NITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): May 20, 2022 (May 18, 2022) BULL HORN HOLDINGS CORP. (Exact name of registrant as specified in its charter) British Virgin Islands 001-39669 98-1465952 (State or other jurisdiction of
May 20, 2022	EX-99.1	PROMISSORY NOTE Exhibit 99.1 THIS PROMISSORY NOTE (?NOTE?) HAS NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE ?SECURITIES ACT?). THIS NOTE HAS BEEN ACQUIRED FOR INVESTMENT ONLY AND MAY NOT BE SOLD, TRANSFERRED OR ASSIGNED IN THE ABSENCE OF REGISTRATION OF THE RESALE THEREOF UNDER THE SECURITIES ACT OR AN OPINION OF COUNSEL REASONABLY SATISFACTORY IN FORM, SCOPE AND SUBSTANCE TO THE COMPANY
May 10, 2022	EX-10.1	Letter Agreement, dated May 4, 2022, between Bull Horn, Imperial, I-Bankers and Northland (incorporated by reference to Exhibit 10.1 to Bull Horn’s Form 10-Q filed with the SEC on May 10, 2022). Exhibit 10.1 May 4, 2022 Bull Horn Holdings Corp. 801 S. Pointe Drive, Suite TH-1 Miami Beach, Florida 33139 Attn: Robert Striar, Chief Executive Officer Ladies and Gentlemen: Reference is hereby made to that certain Underwriting Agreement, dated October 29, 2020 (the ?Underwriting Agreement?), by and between Bull Horn Holdings Corp., a British Virgin Islands business company (the ?Company?), and
May 10, 2022	SC 13G/A	BHSE / Bull Horn Holdings Corp. / Karpus Management, Inc. - KARPUS INVESTMENT MGT / BULL HORN HOLDINGS - SCHEDULE 13G/A(#1) Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1) * Bull Horn Holdings Corp. (Name of Issuer) Common (Title of Class of Securities) G1686P106 (CUSIP Number) April 30, 2022 (Date of Event Which Requires Filing of This Statement) Check the appropriate box to designate the rule pursuant to which this Schedu
May 10, 2022	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2022 ☐ TRANSITION REPORT P UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2022 ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. 001-39669 BULL HORN HOLDIN
May 3, 2022	EX-10.1	Promissory Note of Bull Horn issued to the sponsor, dated May 2, 2022 (incorporated by reference to Exhibit 10.1 to Bull Horn’s Form 8-K filed with the SEC on May 3, 2022). EX-10.1 2 ea159306ex10-1bullhorn.htm PROMISSORY NOTE ISSUED TO BULL HORN HOLDINGS SPONSOR LLC, DATED MAY 2, 2022. Exhibit 10.1 THIS PROMISSORY NOTE (“NOTE”) HAS NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”). THIS NOTE HAS BEEN ACQUIRED FOR INVESTMENT ONLY AND MAY NOT BE SOLD, TRANSFERRED OR ASSIGNED IN THE ABSENCE OF REGISTRATION OF THE RESALE THEREOF UNDE
May 3, 2022	8-K	Entry into a Material Definitive Agreement, Financial Statements and Exhibits, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): May 3, 2022 (May 2, 2022) BULL HORN HOLDINGS CORP. (Exact name of registrant as specified in its charter) British Virgin Islands 001-39669 98-1465952 (State or other jurisdiction of i
April 27, 2022	8-K	Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits, Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): April 27, 2022 (April 26, 2022) BULL HORN HOLDINGS CORP. (Exact name of registrant as specified in its charter) British Virgin Islands 001-39669 98-1465952 (State or other jurisdictio
April 27, 2022	EX-3.1	Amended and Restated Memorandum and Articles of Association of Bull Horn, filed on April 27, 2022 (incorporated by reference to Exhibit 3.1 of Bull Horn’s Form 8-K, filed with the SEC on April 27, 2022). EX-3.1 2 ea158950ex3-1bullhorn.htm AMENDMENT TO AMENDED AND RESTATED MEMORANDUM AND ARTICLES OF ASSOCIATION Exhibit 3.1 Territory of the British Virgin Islands The BVI Business Companies Act, 2004 memorandum and articles of association OF Bull Horn Holdings Corp. Incorporated as a BVI Business Company on 27 November 2018 Amended and Restated by Resolution of Members passed on 27 October 2020 and o
April 19, 2022	EX-2.1	Agreement and Plan of Merger, dated as of April 18, 2022, by and among Bull Horn, Merger Sub and Coeptis. Exhibit 2.1 EXECUTION COPY CONFIDENTIAL AGREEMENT AND PLAN OF MERGER by and among BULL HORN HOLDINGS CORP., as the Purchaser, BH MERGER SUB, INC., as Merger Sub, and COEPTIS THERAPEUTICS, INC., as the Company, Dated as of April 18, 2022 TABLE OF CONTENTS Page I. MERGER 2 1.1. Merger 2 1.2. Transaction Effective Time 2 1.3. Effect of the Merger 2 1.4. Tax Treatment 2 1.5. Certificate of Incorporati
April 19, 2022	EX-2.1	Agreement and Plan of Merger and Reorganization, dated as of April 18, 2022, by and among Bull Horn Holdings Corp., a British Virgin Island corporation, BH Acquisition Sub, a Delaware corporation and Coeptis Therapeutics, Inc., a Delaware corporation EX-2.1 2 ea158593ex2-1bullhorn.htm AGREEMENT AND PLAN OF MERGER, DATED AS OF APRIL 18, 2022, BY AND AMONG BULL HORN, MERGER SUB AND COEPTIS Exhibit 2.1 EXECUTION COPY CONFIDENTIAL AGREEMENT AND PLAN OF MERGER by and among BULL HORN HOLDINGS CORP., as the Purchaser, BH MERGER SUB, INC., as Merger Sub, and COEPTIS THERAPEUTICS, INC., as the Company, Dated as of April 18, 2022 TABLE OF CONTENTS Page
April 19, 2022	8-K	Regulation FD Disclosure, Entry into a Material Definitive Agreement, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): April 19, 2022 (April 18, 2022) BULL HORN HOLDINGS CORP. (Exact name of registrant as specified in its charter) British Virgin Islands 001-39669 98-1465952 (State or other jurisdictio
April 19, 2022	EX-99.1	Coeptis Therapeutics, Inc. and Bull Horn Holdings Corp. Announce Merger Agreement Transaction expected to accelerate Coeptis’ ability to progress its innovative cell therapy platforms for cancer David Mehalick of Coeptis to serve as Chief Executive O EX-99.1 4 ea158593ex99-1bullhorn.htm PRESS RELEASE, DATED APRIL 19, 2022 Exhibit 99.1 Press Release Coeptis Therapeutics, Inc. and Bull Horn Holdings Corp. Announce Merger Agreement Transaction expected to accelerate Coeptis’ ability to progress its innovative cell therapy platforms for cancer David Mehalick of Coeptis to serve as Chief Executive Officer; Chris Calise of Bull Horn to join the Boar
April 19, 2022	EX-99.1	Coeptis Therapeutics, Inc. and Bull Horn Holdings Corp. Announce Merger Agreement Transaction expected to accelerate Coeptis’ ability to progress its innovative cell therapy platforms for cancer David Mehalick of Coeptis to serve as Chief Executive O Exhibit 99.1 Press Release Coeptis Therapeutics, Inc. and Bull Horn Holdings Corp. Announce Merger Agreement Transaction expected to accelerate Coeptis? ability to progress its innovative cell therapy platforms for cancer David Mehalick of Coeptis to serve as Chief Executive Officer; Chris Calise of Bull Horn to join the Board of Directors Merger anticipated to close in third quarter 2022; combine
April 19, 2022	DEFA14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 DEFA14A 1 ea158622-defa14abullhorn.htm DEFINITIVE ADDITIONAL MATERIALS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Comm
April 19, 2022	EX-10.1	Form of Voting Agreement, dated as of April 18, 2022, by and among Bull Horn, Coeptis and certain stockholders of Coeptis (incorporated by reference to Exhibit 10.1 of Bull Horn’s Form 8-K, filed with the SEC on April 19, 2022, and also included as Annex A to the proxy statement/prospectus). EX-10.1 3 ea158593ex10-1bullhorn.htm FORM OF VOTING AGREEMENT, DATED AS OF APRIL 18, 2022, BY AND AMONG BULL HORN, COEPTIS AND CERTAIN STOCKHOLDERS OF COEPTIS Exhibit 10.1 FINAL FORM CONFIDENTIAL Exhibit A FORM OF VOTING AND SUPPORT AGREEMENT This Voting and Support Agreement (this “Agreement”) is made as of April 18, 2022, by and among (i) Bull Horn Holdings Corp., a British Virgin Islands busine
April 19, 2022	425	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): April 19, 2022 (April 18, 2022) B UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): April 19, 2022 (April 18, 2022) BULL HORN HOLDINGS CORP. (Exact name of registrant as specified in its charter) British Virgin Islands 001-39669 98-1465952 (State or other jurisdictio
April 19, 2022	EX-10.1	Form of Voting Agreement, dated as of April 18, 2022, by and among Bull Horn, Coeptis and certain stockholders of Coeptis. EX-10.1 3 ea158593ex10-1bullhorn.htm FORM OF VOTING AGREEMENT, DATED AS OF APRIL 18, 2022, BY AND AMONG BULL HORN, COEPTIS AND CERTAIN STOCKHOLDERS OF COEPTIS Exhibit 10.1 FINAL FORM CONFIDENTIAL Exhibit A FORM OF VOTING AND SUPPORT AGREEMENT This Voting and Support Agreement (this “Agreement”) is made as of April 18, 2022, by and among (i) Bull Horn Holdings Corp., a British Virgin Islands busine
April 19, 2022	DEFA14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 DEFA14A 1 ea158605-defa14abullhorn.htm DEFINITIVE ADDITIONAL MATERIALS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Comm

BULL / Webull Corporation - Pengajuan SECLaporan Tahunan, Pernyataan Proksi

Mga Batayang Estadistika

SEC Filings

SEC Filings (Chronological Order)

Other Listings